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I. INTRODUCTION 
Cystic Fibrosis (CF) is the most common life-threatening hereditary disorder 
among Caucasians and affects more than 100,000 people worldwide (reviewed in 
KLIMOVA et al., 2017). It is caused by mutations in the gene coding for the 
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) (WELSH & 
SMITH, 1993), leading to a defective anion transport on epithelial surfaces. CF 
constitutes a complex multi-organ disease affecting the airways, the 
gastrointestinal tract, including the pancreas and the hepatobiliary system, as well 
as the reproductive tract and the sweat glands, whereby clinical expression in 
individuals with CF shows a considerable variability (reviewed in AVERILL et 
al., 2017; HARUTYUNYAN et al., 2018; PARANJAPE & MOGAYZEL, 2018). 
While many organ systems can be affected, the major cause of morbidity and 
mortality is traced to pulmonary insufficiency (reviewed in CUTTING, 2015; 
PARKINS et al., 2018). Although CF remains incurable, the overall knowledge 
about the disease increased tremendously, so that not only life expectancy of up to 
40 years, but also the quality of patients’ life has significantly been improved over 
the last decades. 
For a better understanding of pathophysiological mechanisms in CF and for 
developing novel therapeutic approaches, animal models turned out to be essential 
tools (reviewed in SEMANIAKOU et al., 2018). From the CF animal models 
developed so far in six species (mouse, rat, zebrafish, sheep, ferret and pig), the 
porcine CF model proves to be the model showing the closest similarity to 
hallmark features of human CF disease (reviewed in CUTTING, 2015). However, 
a lethal neonatal meconium ileus (MI) occurs in 100 % of all CF piglets 
(ROGERS et al., 2008b; KLYMIUK et al., 2012). If the intestinal obstruction is 
not corrected, CF piglets die within 48 hours after birth, considerably limiting the 
utility of pigs as animal models in CF research (KLYMIUK et al., 2012). 
Nonetheless, a previous thesis done at the Chair for Molecular Animal Breeding 
and Biotechnology, describes the occurrence of three CF piglets (#2850, #3137 
and #4424) that showed a clear improved intestinal phenotype as meconium has 
passed autonomously; all other characteristic features of CF were still present 
(DMOCHEWITZ, 2016). Subsequent genome-wide analysis revealed the 
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hypothesis of two independent modifying loci on chromosome 10 (25.8–25.9 Mb) 
and on chromosome 16 (4.7–5.2 Mb) to rescue the severe intestinal phenotype. In 
my work, the hypothesis was tested and therefore the frequency of the desired 
genotype constellation on both candidate regions was enriched in the CF breeding 
herd in order to increase the probability of an improved intestinal manifestation in 
CF piglets. Eventually, an alternative evaluation of the genetic diversity was 
performed by genome-wide analysis on the basis of a larger population.  
In addition, a variant respiratory phenotype was observed in some CF piglets 
during my thesis, independently from the CF gut-phenotype. 
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II. REVIEW OF THE LITERATURE 
1. Cystic Fibrosis 
Cystic Fibrosis (CF) is the most common, autosomal recessive monogenic 
disorder among Caucasians and indeed affects more than 100,000 people 
worldwide (reviewed in KLIMOVA et al., 2017). It is caused by mutations in the 
gene coding for the Cystic Fibrosis Transmembrane Conductance Regulator 
(CFTR), a controlled anion channel (WELSH & SMITH, 1993). 
As early as in the Middle Ages, interesting notes told about children whose brows 
tasted salty and who died precociously (AGRONS et al., 1996), but only in 1938 
Andersen firstly described clinical features of pancreatic fibrosis and pulmonary 
disease and finally introduced the term “cystic fibrosis” (ANDERSEN, 1938). 
Abnormal sweat gland electrolyte secretion was detected in 1953 (DI 
SANT'AGNESE et al., 1953), laying the foundation for the development of the 
“sweat test” in 1959 by Gibson and Cooke (GIBSON & COOKE, 1959) as a 
valuable diagnostic tool for CF, which is still in common use today. In 1983 the 
defective permeability of epithelium to chloride ions was recognized as the basic 
physiologic aberration in CF (QUINTON, 1983). With the identification of the 
disease causing CFTR gene (RIORDAN et al., 1989), a great breakthrough has 
been done and new diagnostic tests, prospects for novel therapeutic approaches 
and opportunities for further research came up. 
 
The history of Cystic Fibrosis treatment can be considered a paradigm of the 
successful performance by collaborative international exertion in the basic and 
clinical research (reviewed in CASTELLANI & ASSAEL, 2017). Although CF 
remains incurable, the overall knowledge about the disease increased 
tremendously, so that not only life expectancy, but also the quality of patients’ life 
has significantly been improved over the last decades. 
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1.1. Genetics of Cystic Fibrosis 
The identification of the CFTR gene in 1989 (RIORDAN et al., 1989) was a major 
breakthrough and paved the way for a more detailed diagnosis of CF, a better 
insight into the clinical features, and actually laid the foundation for new 
therapeutic agents (reviewed in DAVIS, 2006). The CFTR gene is located on the 
long arm of chromosome 7, consists of 27 exons, spanning over 250 kb and 
encodes the CFTR protein, which comprises 1,480 amino acids (MARINO et al., 
1991; reviewed in DAVIS, 2006; reviewed in FANEN et al., 2014). CFTR is a 
membrane protein, expressed in many epithelial cells within the airways, 
pancreas, liver, intestine, sweat glands and vas deferens (reviewed in DAVIS, 
2006) and functions as a cAMP-regulated channel, which transports anions, 
including chloride and bicarbonate. It belongs to the ABC-transporter family and 
is the only member of this family operating as an ion channel (reviewed in MENG 
et al., 2017; ROGERS et al., 2019). 
CFTR structurally consists of five domains: two membrane-spanning domains 
(MSDs), taking part in the formation of the chloride channel pore, two nucleotide-
binding domains (NBDs), interacting with cytosolic nucleotides, and one 
intracellular regulatory region (R) with multiple phosphorylation consensus sites. 
Coordinated interaction of NBDs and R domain systematically regulate channel 
activity (reviewed in WELSH & SMITH, 1993; MENG et al., 2017). Presently, 
there are more than 2,000 different mutations listed in the Cystic Fibrosis 
Mutation Database (CFTR1, 2015), of which at least 280 mutations are known to 
cause disease (IVANOV et al., 2018). The most common mutation worldwide, 
characterized by deletion of a single phenylalanine in position 508 (F508del), 
affects around 66 % of all CF patients (reviewed in RATJEN, 2009; CFTR1, 
2015). Individuals homozygous for F508del represent the most common CFTR 
genotype, namely 50 % of all patients (CUTTING, 2010). 
Based on their functional consequences on the CFTR protein, mutations are 
classified into six different groups (WELSH & SMITH, 1993; reviewed in 
ROGERS et al., 2019). Nonsense or splicing mutations lead to a complete absence 
of full-length, functional CFTR protein synthesis and are summarized in class I. 
Class II mutations, including the F508del mutation, stem from CFTR misfolding, 
resulting in a CFTR protein that fails to traffic through the endoplasmic reticulum 
to the cell surface. Mutant proteins that indeed reach the plasma membrane, but 
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due to mutations in the NBDs, do not respond to activation stimuli, such as 
phosphorylation, are cumulated in class III. As a result, these types of mutations 
lead to decreased chloride channel activity. A diminished chloride conductance 
defect is summed up in class IV mutations. Class V and VI mutations lead to 
normal CFTR protein, but there is either less amount of functional protein (class 
V) or less stability at the apical membrane combined with an increased turnover in 
the plasma membrane (class VI). Class I-III mutations are associated with the 
classical CF phenotype, whereas the other defects lead to milder phenotypes 
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1.2. Pathophysiology of Cystic Fibrosis 
Since the detection of the disease-causing CFTR gene, the knowledge of CF 
pathophysiology has increased significantly. Nevertheless, there are many aspects 
that still remain unclear and necessarily need to be clarified in order to 
conceivably escape the still unavoidable outcome of progressive lung dysfunction, 
the major cause of morbidity and mortality in CF-patients (reviewed in 
CUTTING, 2015). 
In summary, an absent or malfunctioning CFTR protein leads to reduced chloride 
and bicarbonate conductance on the apical membrane of epithelial cells, resulting 
in dehydration and acidification of mucosal surfaces (reviewed in RATJEN, 2009; 
GENTZSCH & MALL, 2018). The so formed sticky and viscous mucus obstructs 
the luminal compartments of the affected organs, such as the lungs, the intestine 
and the pancreas. 
It is of note, that, apart from being a chloride and bicarbonate channel, CFTR also 
acts as a regulator of other membrane channels. In this context, active CFTR 
inhibits the epithelial sodium channel ENaC, causing the absorption of sodium 
and water from the airway lumen (reviewed in CASTELLANI et al., 2018b), as 
well as chloride efflux via the outwardly rectifying chloride channel ORCC 
(reviewed in RATJEN, 2009). 
From the beginning there were two different hypotheses, both of them trying to 
find a possible explanation for the development of CF lung disease, which reflects 
a failure of innate defense against bacterial infections (BOUCHER, 2007). The 
first hypothesis, the ‘high salt’ hypothesis, proposes an increased NaCl 
concentration in the airway surface liquid (ASL) as responsible for decreased 
activity of antimicrobial peptides, resulting in chronic airway infections. In 
contrast, the ‘low volume’ hypothesis focuses on the idea, that reduced chloride 
conductance leads to less water efflux, finally resulting in dehydrated airway 
surfaces. In turn, airway surface liquid depletion is recognized as the major cause 
of diminished mucus clearance due to ciliary collapse. Adherent mucus obstructs 
the airways and thus sets the stage for a vicious circle of chronic bacterial 
infection (GOLDMAN et al., 1997) and inflammation, in the end culminating in 
progressive lung dysfunction. 
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1.3. Phenotypical abnormalities in Cystic Fibrosis 
Cystic Fibrosis is a complex multi-organ disease affecting the airways, the 
gastrointestinal tract, including the pancreas and the hepatobiliary system, as well 
as the reproductive tract and the sweat glands, whereby clinical expression in 
individuals with CF shows a comprehensive variability (reviewed in AVERILL et 
al., 2017; HARUTYUNYAN et al., 2018; PARANJAPE & MOGAYZEL, 2018). 
While many organ systems can be affected, the major cause of morbidity and 
mortality is traced to pulmonary insufficiency (reviewed in CUTTING, 2015; 
PARKINS et al., 2018). At birth the lungs of CF patients appear normal, however 
from early age on individuals with common CF typically exhibit progressive 
respiratory manifestations. Impaired mucociliary clearance, resulting in mucus 
obstruction and chronic colonization of the airways by pathogenic bacteria, the 
latter clearly dominated by Staphylococcus aureus and Pseudomonas aeruginosa 
(reviewed in PROESMANS et al., 2008), remain the clinical hallmarks of classic 
CF. Frequent infections with repeated episodes of chronic and acute inflammatory 
and immune reaction lead to airway damage, manifesting as bronchiectasis, 
accompanied by fever, cough, dyspnea and weight loss. Finally, chronic cycles of 
infection and inflammation provoke respiratory failure with clinical end-stage 
lung disease. This is, why lung transplantation often remains the only therapeutic 
option at this stadium. It is of note, that the clinical appearance of CF lung disease 
shows wide variability (reviewed in CASTELLANI & ASSAEL, 2017). 
Up to 90 % of individuals with classic CF suffer from gastrointestinal 
complications. Meconium ileus (MI), a life threatening obstruction of the distal 
small bowel by fetal feces, occurring in 15-20 % of all CF newborns (GUO et al., 
2014), is often the first clinical indication of CF (AGRONS et al., 1996). Its 
occurrence is more frequently associated with more severe CFTR mutations and 
seems to be influenced by additional genetic factors (KNOWLES & DRUMM, 
2012; DUPUIS et al., 2016). Two types of MI are admitted: the simple and the 
complicated form, both occurring with similar frequency (50-58 %). Simple MI 
typically appears in otherwise healthy infants within 48 hours after birth as an 
intestinal obstruction. The complicated form arises earlier and is characterized by 
more severe symptoms like volvulus or microcolon. Resolution of MI requires 
intensive treatment, including rectal infusion of Gastrografin or enema in the case 
of simple MI, as well as surgical intervention in about half of the cases (DUPUIS 
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et al., 2016). Thanks to great progress in the clinical management of MI, the 
survival of newborns with CF and MI increased significantly and is nowadays 
comparable to children with CF who do not suffer from MI.  
Older patients may exhibit intestinal obstruction as well, leading to a sub 
occlusive or fully occlusive manifestation called distal intestinal obstructive 
syndrome (DIOS), that appears in up to 25 % of adult patients (reviewed in 
CASTELLANI & ASSAEL, 2017; SEMANIAKOU et al., 2018). Typically 
conservative measures like oral rehydration or osmotic laxatives are 
recommended (KELLY & BUXBAUM, 2015).            
Another feature of classic CF, affecting 85-90 % of adults, is pancreatic exocrine 
insufficiency (reviewed in AVERILL et al., 2017; HARUTYUNYAN et al., 
2018). Decreased levels of pancreatic enzymes lead to fat malabsorption, causing 
steatorrhea, malnutrition, deficiency of fat-soluble vitamins and characteristic 
fatty and foul-smelling stool. Similar to the occurrence of MI, pancreatic 
insufficiency is usually also associated with severe class I-III CFTR mutations 
(DURNO et al., 2002). As a result of progressive damage of pancreatic tissue, the 
pancreas can also lose its endocrine function, leading to Cystic Fibrosis-related 
diabetes mellitus (CFRD), which is a unique combination of type I and type II 
diabetes and can be handled with insulin.  
Often hepatobiliary manifestation in CF is not clinically relevant. However, in 
some patients (3-5 %) Cystic Fibrosis-related liver disease (CFLD) is severe and 
counts as the third most common cause of mortality in CF individuals after 
respiratory failure and complications following transplantation. Usually, the onset 
of liver disease in the second decade of life or even later is characterized by fatty 
liver, fibrosis, biliary cirrhosis and portal hypertension. The so-called ‘micro-
gallbladder’ is another reported abnormality in 10-30 % of all patients with CF 
(reviewed in LAVELLE et al., 2016). It is small or even absent and may be 
nonfunctioning.  
Nearly all males with CF (over 95 %) are infertile due to congenital bilateral 
absence of the vas deferens (CBAVD) and obstructive azoospermia, whereas only 
a small percentage of women suffer from reduced fertility (reviewed in 
EDENBOROUGH, 2001; O'SULLIVAN & FREEDMAN, 2009).  
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1.4. Diagnosis of Cystic Fibrosis 
In most cases, Cystic Fibrosis is diagnosed in the first year of life und normally 
diagnoses are unambiguous (reviewed in AVERILL et al., 2017).  
At the moment there are three main tests to identify whether an individual suffers 
from CF: the newborn screening test, the confirmatory sweat-test and the 
diagnosis of specific mutations of the CFTR gene. 
A diagnosis in the first days of life can be done by newborn screening (NBS), a 
technique established in 1979 (reviewed in COURSE & HANKS, 2019). In this 
test a blood sample is checked for higher than normal levels of pancreatic 
Immunoreactive Trypsinogen (IRT). Laboratories either perform two consecutive 
measurements or, if the first IRT level is increased, execute successive CFTR 
mutation testing (reviewed in PARANJAPE & MOGAYZEL, 2018). Proceeding 
that way, most children diagnosed with CF are nowadays detected when still in an 
asymptomatic stage (reviewed in COURSE & HANKS, 2019). Such an early 
diagnosis has been proven to bring substantial benefits in the following treatment 
and thus in the prognosis of patients with CF. When properly designed and 
managed, screening programs are cost effective and offer a high sensitivity and 
specificity (reviewed in CASTELLANI & ASSAEL, 2017). Over the past two 
decades, there has been a steady increase in national NBS programs. At present, in 
nearly all European countries, as well as in the United States, well-established 
nationwide protocols have been implemented (reviewed in COURSE & HANKS, 
2019). 
The gold-standard for diagnosing CF remains the pilocarpine iontophoresis sweat 
test (reviewed in COURSE & HANKS, 2019), developed by Gibson and Cooke in 
1959, following the knowledge of increased chloride levels in the sweat as an 
unequivocal hallmark of CF (GIBSON & COOKE, 1959). A chloride 
concentration greater than 60 mmol/L is confirmatory of the CF diagnosis, while 
intermediate concentrations (40-60 mmol/L) are only indicative. In such cases, the 
identification of two CF-causing mutations on both alleles clearly verifies the 
before established suspicion (reviewed in KLIMOVA et al., 2017; CASTELLANI 
et al., 2018a). It has to be mentioned, that also in the case of a positive NBS test, a 
sweat test always has to confirm the diagnosis CF (CASTELLANI et al., 2009) . 
Since mutation specific therapies are becoming increasingly available, the 
detection of CFTR mutations in an individual patient is now another important 
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tool (reviewed in DE BOECK et al., 2017). Most common disease-causing 
mutations in the examined population (covering 80-85 % of all mutations in the 
population) are identified with the help of a standard CFTR mutation panel. More 
complex analyses, conducted by certified laboratories, are realized, when two 
CFTR gene mutations could not be identified and the diagnosis of CF is nearly 
confident (diagnostic sweat chloride concentration above 60 mmol/L) or very 
likely due to typical clinical features as previously described. In the course of this, 
the entire CFTR gene is sequenced and after that, large deletions or insertions are 
being evaluated. 
It is of note, that up to 7 % of CF cases are nowadays diagnosed in patients over 
the age of 16 years (reviewed in AVERILL et al., 2017), presenting with recurrent 
pancreatitis, chronic sinusitis or CBAVD. Often these patients exhibit one ‘mild’ 
CFTR mutation and retain a residual chloride channel activity. With only 10 % of 
the normal levels of CFTR mRNA remaining, individuals can show normal lung 
and pancreatic function, what is a formative difference from the before described 
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1.5. Treatment approaches for chronic aspects of Cystic Fibrosis 
When first described in 1938, CF usually resulted in death during infancy 
(reviewed in CASTELLANI et al., 2018a; ROGERS et al., 2019). Early diagnosis, 
substantial progress in the management of especially pulmonary CF disease, 
important new therapy approaches and the establishment of multi-disciplinary 
treatment centers in the 1950s, altogether greatly improved the duration and 
particularly the quality of patients’ life. Presently, 40-50 % of all CF patients are 
adults with a life expectancy of up to 40 years in countries with well-established 
CF programs (HODSON et al., 2008). For people born after the year 2000 it is 
even projected to be 50 years (HURLEY et al., 2014). CF cannot be cured, but 
with the help of careful monitoring and early aggressive pharmacological 
strategies, symptoms can be delayed.  
Treatment approaches primarily focus on pulmonary manifestation of CF. In early 
stages of the disease, non-pharmacological treatment, mainly focusing on chest 
physical therapy, can help to loosen mucus (reviewed in KLIMOVA et al., 2017). 
The main challenge in CF remains the prevention and control of lung infections 
(reviewed in CASTELLANI & ASSAEL, 2017; KLIMOVA et al., 2017; 
RAFEEQ & MURAD, 2017). In this context, antibiotics in a high-dosage regime 
are prescribed, mainly consisting of inhaled forms of azithromycin, tobramycin, 
aztreonam and levofloxacin. Despite aggressive preventive measures, bacterial 
colonization of the lower airways, usually ending up in progressive lung damage, 
just like repeated episodes of inflammatory and immune action, remain major 
clinical difficulties. Anti-inflammatory therapy is able to slow down the 
progression of lung disease (reviewed in CHENG et al., 2013) and comprises the 
intake of ibuprofen (LANDS et al., 2007), as well as inhaled (beclomethasone, 
budesonide and fluticasone) or systemic (prednisone) corticosteroids. Another 
important aspect in dealing with CF pulmonary manifestation is the use of 
mucoactive substances, which help to remove thick, sticky mucus from the lungs 
and further dilate the airways. Mucolytics can be divided into non-specific, such 
as ambroxol, acetylcysteine and mesna, and in CF-specific like amiloride, NaCl 
and dornase α. In the worst cases, respiratory failure and end-stage lung disease 
make a lung transplantation, as the only remaining therapeutic option, necessary. 
Pancreatic insufficiency is treated with well-established pancreatic enzyme 
replacement therapy rich in lipase, protease and amylase. Furthermore, a strict 
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high-energy and high-fat dietary nutrition and the supplementation of vitamins is 
mandatory (reviewed in KLIMOVA et al., 2017). 
The therapy of CFLD focuses on improving biliary excretion and bile acid 
composting by oral supplementation of the bile salt ursodeoxycholic acid, which 
normalizes liver function. Only if hepatobiliary disease is complicated by portal 
hypertension, liver transplantation is considered (KELLY & BUXBAUM, 2015). 
Even before the identification of the CFTR gene, genetic based therapy was 
suggested as possible treatment for CF (reviewed in GILL & HYDE, 2014). Gene 
therapy approaches mainly focus on gene complementation, where wild type 
(WT) CFTR cDNA is delivered to cells suffering from impaired CFTR function, a 
method feasible for all classes of mutations. A clinical study by British scientists, 
administering monthly treatments of a nebulized gene/liposome complex, run in 
clinical trial phase II and showed modest, but positive results in favor of improved 
lung function in 3.7 % of participating CF patients (reviewed in CASTELLANI & 
ASSAEL, 2017). 
With the introduction of so-called CFTR modulators, treatment methods shifted 
from only symptomatic therapy towards personalized approaches, adjusted to the 
patients’ underlying CFTR mutation (reviewed in SKOV et al., 2019). At the 
moment there are three different types of modulators available: potentiators, used 
in class III or IV mutations, raise the function of CFTR channels by increasing the 
channel open probability. Correctors, which augment the intracellular processing 
of class II mutations, allowing more protein to reach the plasma membrane. 
Moreover, read-through agents promote ribosomal read-through in class I CFTR 
mutations (reviewed in BRODLIE et al., 2015). The first available modulator was 
ivacaftor (Kalydeco), targeting class III mutations such as G551D, which is 
carried by 4 to 5 % of CF patients (ROWE et al., 2014). Ivacaftor was shown to 
significantly improve clinical parameters such as lung function and has actually 
been approved for treating patients with 38 different class III and IV mutations 
(reviewed in ROGERS et al., 2019). In 2015, the combination of ivacaftor 
together with the corrector lumacaftor (VX-809) was established in order to 
correct the most common class II mutation F508del (WAINWRIGHT et al., 
2015). Unfortunately, compared to the previously described ivacaftor 
monotherapy, the effects of this combined method on lung function were 
relatively modest. Similar clinical effects, also tested in F508del mutations, have 
been observed with another potentiator/corrector combination ivacaftor/tezacaftor 
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(ROWE et al., 2017; TAYLOR-COUSAR et al., 2017). Ataluren (PTC124) is a 
read-through agent and has been trialed for use in class I mutations, affecting 
approximately 10 % of CF patients. It is now in phase III of clinical trials and so 
far, it showed moderate clinical improvement (KEREM et al., 2014). New and 
potentially more effective so-called next-generation modulators, aiming to be 
available for a much larger CF population, are presently tested in ongoing studies 
(reviewed in SKOV et al., 2019). 
In summary it can be said, that, despite the positive outcomes of all the new 
agents, there are still limitations, including high costs for long-term treatment 
(reviewed in WHITING et al., 2014) and particularly the indispensable need to 
continue other symptomatic treatment (reviewed in RAFEEQ & MURAD, 2017). 
The development and improvement of novel treatment procedures for an even 
larger community of CF patients is a crucial need to enhance the patients’ quality 














II. Review of the literature    14 
2. Animal models for Cystic Fibrosis 
Animal models are essential tools for better understanding pathophysiological 
mechanisms in Cystic Fibrosis and for developing new therapeutic approaches 
(reviewed in SEMANIAKOU et al., 2018). CFTR-deficient animal models offer 
several advantages for studying CF disease (reviewed in OLIVIER et al., 2015). 
They can be studied early in life, whereas studies in CF infants and children are 
limited due to ethical concerns. Moreover, animal models allow for controlled 
comparison of organ systems and even of the clinical spectrum between different 
species. Thus, they do not only give greater insights into CF pathogenesis, but 
also help to identify additional genetic modifiers possibly influencing the disease. 
Currently, CF model in six different species are available (mouse, rat, zebrafish, 
sheep, ferret and pig) and demonstrate the complexity of human CF 
manifestations, whereby various models present different specific advantages, but 
also major limitations (reviewed in SEMANIAKOU et al., 2018). 
 
2.1. Animal models for Cystic Fibrosis (apart from the pig) 
Shortly after the identification of the CFTR gene in 1989, the first CF mouse 
model was generated (SNOUWAERT et al., 1992). The most prominent hallmark 
in CF mice is the severe intestinal obstruction, including mucus accumulation, 
goblet cell hyperplasia and crypt dilatation, symptoms comparable with human 
intestinal manifestation (reviewed in GRUBB & BOUCHER, 1999). In contrast to 
CF patients in whom pancreatic insufficiency and liver disease are major features, 
CF mice develop only mild pancreatic disease (SNOUWAERT et al., 1992) and 
no obvious liver pathology (reviewed in ROSEN et al., 2018). Most of the male 
CF mice exhibit reduced fertility, but the complete bilateral absence of the vas 
deferens, typical for male humans, is missing (LEUNG et al., 1996; LAVELLE et 
al., 2016). The main problem of the CF mouse, limiting its usage as an animal 
model, is the lack of replicating CF-typical substantial und spontaneous bacterial 
infection and inflammation in the lungs (reviewed in GUILBAULT et al., 2007). 
A possible explanation for this divergent respiratory phenotype could be an 
adaptive dominance of the calcium-activated chloride channel (CACC), 
compensating the defective chloride transport (reviewed in MCCARRON et al., 
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2018). 
CF rat models are characterized by intestinal obstruction at weaning, complete 
bilateral absence of the vas deferens and missing signs of obvious hepatobiliary 
and pancreatic disease (TUGGLE et al., 2014). While CF rats do not 
spontaneously develop lung infection and inflammation, they still share 
respiratory abnormalities consistent with humans, such as congenital tracheal 
defects with reduced cartilage and gland area. 
The CF zebrafish is a unique model of pancreatic disease progression in all 
developmental stages, demonstrating that pancreatic dysfunction starts early in 
life (NAVIS & BAGNAT, 2015). 
FAN et al. (2018) generated the first CF sheep model, which is characterized by 
intestinal obstruction with 100 % incidence in CF KO lambs, pancreatic fibrosis, 
hepatobiliary abnormalities, including fibrosis and cirrhosis, as well as the 
absence of vas deferens in male individuals. However, lung pathology is not 
detectable. 
Due to similarity in lung cell biology and anatomy to human CF patients, the 
ferret is a good animal model for CF research (reviewed in LAVELLE et al., 
2016). Ferret CF models show a more severe intestinal phenotype compared to 
humans, as MI is present in approximately 75 % of CF ferret kits (SUN et al., 
2010), resulting in death within 36 hours (reviewed in FISHER et al., 2011). 
Similar to human CF infants, CF KO kits are born with only mild pancreatic 
disease, but very early in life pancreatic inflammation is starting and within the 
first months the pancreas undergoes rapid tissue deterioration, finally resulting in 
pancreatic insufficiency in 85 % of adult CF ferrets and characteristics of CF-
related diabetes mellitus (OLIVIER et al., 2012). While the hepatobiliary system 
appears normal at birth, increased liver enzymes indicate an early onset of liver 
disease and even gallbladder abnormalities are present in the majority of CF 
ferrets older than one month (SUN et al., 2014). An absent or degenerated vas 
deferens is another characteristic, typically found in CF ferrets. Most importantly, 
ferret models mirror the human respiratory phenotype, characterized by impaired 
mucociliary clearance, mucus-obstruction of the airways and submucosal glands, 
and particularly the development of spontaneous lung infections soon after birth 
(SUN et al., 2010; SUN et al., 2014). 
II. Review of the literature    16 
2.2. The pig as an animal model for Cystic Fibrosis 
From the CF animal models developed so far, the porcine CF model proves to be 
the model showing the closest similarity to typical CF phenotype in humans 
(reviewed in CUTTING, 2015). In view of pulmonary insufficiency, presenting 
the leading cause of mortality in CF patients, the pig as an animal model offers 
potential advantages, as its lung share many features with human lungs (ROGERS 
et al., 2008a; WELSH et al., 2009; AIGNER et al., 2010). In general, pigs and 
humans have a lot of similarities in terms of anatomy, physiology, histology, 
immunology, metabolism and even genomics. Moreover, the early sexual 
maturity, a short generation time and large litter sizes also recommend the pig as 
an ideal large animal model. The longevity of pigs enables for examining 
pathophysiological mechanisms in CF and long-term efficacy of pharmacological 
and other treatment approaches.  
So far, three different porcine CF models, either carrying the complete disruption 
of both CFTR alleles (ROGERS et al., 2008b; KLYMIUK et al., 2012), or 
carrying the most common CF-associated mutation F508del (ROGERS et al., 
2008a), have been generated. Rogers and colleagues used recombinant adeno-
associated virus (rAAV) vectors targeting the porcine CFTR gene in fetal 
fibroblasts, followed by somatic cell nuclear transfer (SCNT) and embryo transfer 
(ET) to produce male heterozygous CFTR+/- offspring. At sexual maturity they 
were bred selectively over two generations by initially generating further male and 
also female heterozygotes in order to finally produce CFTR-/- piglets (ROGERS et 
al., 2008a). The first European pig model of CF was established by KLYMIUK et 
al. (2012) by using modified bacterial artificial chromosome (BAC) vectors for 
sequential targeting of the CFTR gene in porcine primary kidney cells. 
Cystic Fibrosis pigs recapitulate many of the human phenotypical manifestations 
of CF. In newborn CF piglets, pancreatic insufficiency develops spontaneously, 
characterized by a variable severity of exocrine tissue destruction (ROGERS et 
al., 2008b; MEYERHOLZ et al., 2010b; KLYMIUK et al., 2012). Histologically, 
small and degenerative lobules with loose adipose tissue, mucus-dilated ducts, 
obstructed by eosinophilic material, and even signs of mild inflammation are 
generally detectable. Morphologically, pancreatic endocrine tissue appears intact 
(ROGERS et al., 2008b), however, glycemic abnormalities and even defects in 
insulin secretion are present findings in newborn CF pigs (UC et al., 2014). 
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Indeed, CF piglets demonstrate impaired glucose tolerance and an elevated 
glucose area, resulting in spontaneous hyperglycemia developing over time. 
Interestingly, obvious functional alterations in the pancreas of CF pigs are not 
associated with a decrease in islet cell mass, suggesting, that, independent of 
structural islet loss, functional deviations in pancreatic islets contribute to the 
early pathogenesis of CF-related diabetes mellitus (UC et al., 2014). 
The liver of CF KO pigs infrequently exposes mild to moderate hepatic lesions, 
whereby signs of focal biliary cirrhosis, including increased cellular 
inflammation, bile ductal hyperplasia and mild fibrosis, are present. While all 
CFTR-/- piglets exhibit a micro-gallbladder, filled with mucin-containing material, 
in human CF patients this phenotypical abnormality occurs in only 10-30 % of all 
cases (reviewed in LAVELLE et al., 2016). It is of note, that the hepatic changes 
in CF pigs are irregular not only between different areas within the same tissue, 
but also between different individuals (KLYMIUK et al., 2012). 
Moreover, male CF KO piglets reveal a degenerated or absent vas deferens, and in 
some cases also epididymis atresia, comparable with changes typically found in 
human CF patients (PIERUCCI-ALVES et al., 2011). 
 
2.2.1. The respiratory phenotype in Cystic Fibrosis pigs 
Due to anatomical, histological and physiological similarities between the human 
and porcine lung, the pig model presents an ideal model to examine 
pathophysiological mechanisms in CF lung disease (AIGNER et al., 2010). 
Interestingly, the porcine respiratory tract has already been used for a long time to 
study pulmonary abnormalities that are relevant to CF, such as infection and 
inflammation procedures (BRADLEY et al., 1976; PABST & BINNS, 1994).          
In contrast to most of the CF animal models generated so far, the porcine CF 
model demonstrates several respiratory abnormalities. Common findings in all CF 
piglets are tracheal abnormalities, including a triangular to oval shaped trachea, in 
contrast to the circular shape in WT controls, reduced tracheal caliber extended 
through the mainstem bronchi, as well as thicker and more discontinuous 
cartilages (ROGERS et al., 2008b; KLYMIUK et al., 2012). Due to altered 
orientation of smooth muscle cell bundles, the caudal trachea and the large 
bronchi exhibit a variable thickening of the posterior wall. Moreover, submucosal 
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glands occur with similar frequency compared to control airways, but CF glands 
are small and hypoplastic (MEYERHOLZ et al., 2010a). In summary, the 
congenital tracheal defects are similar to changes found in CF infants (reviewed in 
MEYERHOLZ et al., 2010a; STOLTZ et al., 2015) and are furthermore awarded 
to contribute to CF disease development during postnatal life (WELSH et al., 
2009; MEYERHOLZ et al., 2010a). Nevertheless, specific mechanisms for 
tracheal abnormalities and the question, how absent CFTR induces these effects 
during development, are still unknown (MEYERHOLZ et al., 2010a). 
The lungs of newborn CF piglets morphologically appear normal at birth without 
evidence of pathological abnormalities (ROGERS et al., 2008b). Only within 
weeks to months after birth, they spontaneously develop characteristic features of 
CF lung disease, including infection, inflammation, mucus accumulation and 
remodeling procedures (STOLTZ et al., 2010). Interestingly, the manifestation of 
CF respiratory phenotype is, similar to humans, heterogeneous within and among 
pigs. Although newborn CF pigs morphologically do not show signs of 
inflammation, compared to non-CF littermates their lungs are less sterile. 
Harboring a huge amount of environmental bacteria led to the conclusion, that this 
is an equal opportunity host-defense defect (STOLTZ et al., 2015). Even after 
intrapulmonary bacterial challenge, CF piglets actually fail to eliminate bacteria, 
suggesting that airway infection precedes lung inflammation and not vice versa 
(STOLTZ et al., 2010). The reason for diminished degree of bacterial killing has 
been directly linked to reduced CFTR-dependent bicarbonate secretion, resulting 
in acidic airway surface liquid and decreased antibacterial activity (reviewed in 
STOLTZ et al., 2015).  Suspecting that host-defense defects begin within hours of 
birth, preventive measures should be initiated immediately before secondary 
consequences, finally leading to respiratory failure, develop. 
Moreover, pigs with CF demonstrate a defective mucociliary clearance, caused by 
the failure of mucus to detach from submucosal gland ducts. This defect is not 
imputable to insufficient periciliary liquid (BIRKET et al., 2014), but rather to 
basic loss of CFTR anion transport, indicating that this is a primary discrepancy 
and not dependent on processes like infection, inflammation or tissue remodeling 
(reviewed in STOLTZ et al., 2015). 
Most significantly, studies on electrolyte transport in porcine CF airway tissue 
questioned the long-standing hypothesis, that sodium hyperabsorption via the 
epithelial sodium channel ENaC fundamentally contributes to CF pathogenesis. 
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CHEN et al. (2010), indeed demonstrated a lack of chloride conductance and 
impaired bicarbonate transport in airway epithelia in CF piglets, but also a clear 
absence of sodium hyperabsorption. This finding, together with lacking 
inflammation in the lungs of newborn CF pigs, contradicts the claim, that sodium 
hyperabsorption triggers respiratory failure (CHEN et al., 2010; STOLTZ et al., 
2015). Instead, defects in chloride and bicarbonate transport are considered to 
initially initiate the pathogenesis of lung progression in CF patients.  
 
2.2.2. The intestinal phenotype in Cystic Fibrosis pigs 
Unfortunately, the development of CF lung disease in pig models is difficult to 
investigate, as an ever-present, severe intestinal phenotype with fatal meconium 
ileus (MI) represents the most prominent feature in pigs with Cystic Fibrosis. 
While only 15-20 % of all CF infants (GUO et al., 2014) suffer from the intestinal 
obstruction, in CF piglets MI actually occurs with a penetrance of 100 % 
(KLYMIUK et al., 2012). This dissimilarity in penetrance rate may potentially be 
explained by differences in anatomy and physiology combined with a restricted 
genetic background in pigs (ROGERS et al., 2008b). The pathogenesis of MI still 
remains unclear, but possible explanations are the lacking CFTR-mediated 
chloride and/or bicarbonate transport across epithelial membranes or perhaps 
pancreatic dysfunction (STOLTZ et al., 2013). Except from the frequency of 
occurrence, the general features of MI in pigs closely replicate those observed in 
humans. The site of obstruction ranges from the distal part of the jejunum to the 
proximal spiral colon (ROGERS et al., 2008b; MEYERHOLZ et al., 2010b). An 
atretic and stenotic microcolon with diminished diameter, distal to the site of 
obstruction, is a common finding in piglets with CF. The reason why the intestine 
distal to the site of obstruction fails to develop normally, is still uncertain. It is 
possible, that luminal content either prevents mechanical elongation, or because 
obstruction inhibits a distal transfer of the luminal content, assumed for adequate 
intestinal growth (AMODIO et al., 1986). A variably severe diverticulosis at the 
mesenterial side of the meconium-dilated jejunum is another intestinal lesion 
typically found in CF piglets (KLYMIUK et al., 2012). It appears as saccular 
bulges, histologically composing of lamina propria herniating through the lamina 
muscularis (MEYERHOLZ et al., 2010b). The proposed pathogenesis of such 
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diverticles is described as a combination of increased intraluminal pressure by 
sticky, adherent meconium and hypertrophic smooth muscles during fetal life. For 
some pig breeds a genetic predisposition toward diverticulosis has also been 
discussed (MEYERHOLZ et al., 2010b). The appearance of characteristic 
microcolon and diverticulosis in CF pigs is reported in human CF patients as well, 
however, with a lower incidence rate and a less severity. Further histological 
examinations of the porcine intestine demonstrate atrophic and degenerated villi, 
as well as mucus-obstructed Brunner’s glands in the duodenum, lined by an 
atrophic epithelium (ROGERS et al., 2008b; KLYMIUK et al., 2012). Except as a 
secondary feature, initial signs of intestinal inflammation are not detectable 
(MEYERHOLZ et al., 2010b). 
As clinical signs of an intestinal obstruction, the CF piglets stop eating, evolve 
abdominal distension, show bile-stained emesis and therefore continuously lose 
weight (ROGERS et al., 2008b). If MI is not corrected, CF piglets die within 48 
hours after birth due to multifocal enteritis, peritonitis or even perforation, 
considerably limiting the usage of pigs as animal models in CF research 
(KLYMIUK et al., 2012). In CF infants, therapeutic strategies range from rectal 
infusion of Gastrografin or enema to complex surgical intervention, depending on 
the severity of MI (DUPUIS et al., 2016). However, nonsurgical approaches to 
rectify the intestinal obstruction fail in CF pigs (STOLTZ et al., 2013). Ensuring 
the survival of CF piglets, surgical ileostomy or cecostomy must be performed 
right after birth to bypass the obstruction (ROGERS et al., 2008b; STOLTZ et al., 
2010). Although operative treatment may rescue the severe intestinal phenotype, 
the practicability in pigs is limited by intensive and time-consuming surgical-
procedure as well as post-surgical care (KLYMIUK et al., 2012; GUILLON et al., 
2015). Initially, in some CF pigs a surgical correction is basically not feasible in 
terms of complications associated with MI, such as intestinal atresia or perforation 
(STOLTZ et al., 2013). Even after surgical treatment, there is a high risk for 
postoperative complications, limiting the piglets’ lifespan (KLYMIUK et al., 
2012). These aspects, in addition to associated high costs, compromise surgical 
approaches as a regular technique to overcome the lethal intestinal phenotype in 
CF pigs (STOLTZ et al., 2013).  
To circumvent these limitations, the prevention of MI rather than its treatment 
would obviously be an alternative method. Transgenic expression of CFTR under 
the control of gut-specific promoter results in an exclusive expression in the 
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intestine, while other organ systems stay unaffected (STOLTZ et al., 2013). As, in 
this way, the intestinal phenotype is able to be alleviated or even rescued, all other 
characteristic features of CF are still present. ZHOU et al. (1994) set the stage by 
using the rat intestinal fatty acid-binding protein (iFABP) promoter to express 
human CFTR in a murine model of CF, resulting in functional correction of cell 
hyperplasia and restored chloride secretion. STOLTZ et al. (2013) adopted that 
strategy to weaken the lethal intestinal phenotype, resulting in a “gut-corrected” 
porcine model of Cystic Fibrosis. They used the rat iFABP promoter to express 
WT porcine CFTR protein (pCFTR) in CF KO pigs (STOLTZ et al., 2013). In this 
study, piglets from 3 out of 5 transgenic lines had an improved intestinal 
phenotype, while still exhibiting pancreatic destruction, liver disorder and lung 
disease. An expression rate of approximately 20 % of WT CFTR seems to be 
adequate to largely prevent MI. It has to be mentioned, that a supportive treatment 
with Gastrografin enemas is still necessary to assure the piglets’ survival. 
Interestingly, BALLARD et al. (2016) evaluated the “gut-corrected” approach in 
CF pigs and unexpectedly found other complications among the piglets, including 
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3. Modifier genes in Cystic Fibrosis 
In general terms, Cystic Fibrosis is a monogenic recessive Mendelian disorder 
with complex, heterogeneous phenotypic expression (reviewed in WEILER & 
DRUMM, 2013; O'NEAL & KNOWLES, 2018). Apart from the causative CFTR 
defect itself, there are multiple sources that contribute to the striking phenotypic 
diversity, including the specific CFTR mutation, environmental factors, as well as 
additional non-CFTR genetic influences, so called ‘modifier genes’. Each of the 
affected organ systems in CF demonstrates a specific phenotypic variability and 
uniquely responds to CFTR mutations and modifier effects. The correlation 
between CFTR genotype and clinical manifestation of the disease is well-known 
(KEREM et al., 1990). However, even among patients carrying the same CFTR 
mutation, there is a wide range of clinical manifestation, most notably lung 
disease diversity. As early as 1990, the potential role of genetic modifiers in 
determining the complexity of CF, has been proposed (SANTIS et al., 1990). 
Twin and sibling studies, determining the relative contribution of genetic and 
environmental factors, demonstrated high degrees of heritability for several traits, 
such as the severity of lung disease (MEKUS et al., 2000; VANSCOY et al., 
2007), the risk for developing CFRD (BLACKMAN et al., 2009), early exocrine 
pancreatic insufficiency (SONTAG et al., 2006) and also the occurrence of 
intestinal obstruction at birth (BLACKMAN et al., 2006). In sum, those studies 
generally pointed to significant role of genetic modifiers in disease presentation, 
but the specific impact on the severity in CF still remains unclear (reviewed in 
SHANTHIKUMAR et al., 2019). 
It is clear, that identifying and comprehensively understanding the effect of non-
CFTR genetic influences in the context of CF pathogenesis and clinical 
variability, help to figure out novel therapeutic targets, hopefully resulting in new 
effective treatment strategies. In this context, observing a patient’s particular 
genetic profile, disease-modifying genes actually open the door to personalized 
medicine (reviewed in WEILER & DRUMM, 2013). 
Initial studies on modifier genes contributing to disease variability, evaluated 
candidate genes or regions implied in pathways that are already known to be 
relevant in CF (reviewed in WEILER & DRUMM, 2013; SHANTHIKUMAR et 
al., 2019). In view of still limited understanding of disease pathophysiology, 
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genetic locations beyond those are not detected. Further challenges of early 
candidate gene approaches are the limitation of statistical power due to relatively 
small cohort sizes and lots of conflicting results (reviewed in BÜSCHER & 
GRASEMANN, 2006). Larger, unbiased studies using a genome-wide approach 
examine either the overall exome, the coding region of the gene, via whole-exome 
sequencing, or all single nucleotide polymorphisms (SNPs), common genetic 
variations in an individual’s DNA sequence (DAVIES et al., 2005), via genome-
wide association study (GWAS). Thus, novel chromosomal regions and genes, 
previously not considered, can be identified. So far, a variety of individual genetic 
modifiers for multiple CF phenotypes has been detected, though there is no single 
definitive contributor that universally predicts disease severity or secondary 
complications (reviewed in DORFMAN, 2012). Rather combinations of genetic 
variants seem to contribute to overall disease manifestation. Due to this complex 
constellations, current study approaches are limited by disparate findings, 
confined replication and a relative lack of clinical influence. Future work has to 
overcome these limitations and finally assess, whether validated modifiers can 
actually be used in clinical management of CF patients. 
 
3.1. Gene modifiers for the respiratory phenotype in Cystic Fibrosis 
Considering the great relevance of pulmonary insufficiency in the progression of 
CF, the main focus of gene modifier approaches is the identification of additional 
non-CFTR genetic influences for lung disease progression (reviewed in O'NEAL 
& KNOWLES, 2018). The complex, heterogeneous phenotypic expression in CF 
appears, as previously mentioned, even among CF patients with the same CFTR 
mutation. While some patients exhibit relatively mild lung disease until 
adolescence and adulthood, others show a faster decline in lung function and 
suffer from poor respiratory condition even at very young age (KEREM et al., 
1990). Also, in various CF animal models, the manifestation of pulmonary disease 
severely differs, as ferrets and pigs spontaneously develop lung infection and 
inflammation, whereas mice, rats and sheep lack this CF-typical abnormality. It 
was determined, that genetic modifiers could account for 50-80 % of lung disease 
variability in CF patients carrying an equal CFTR genotype (VANSCOY et al., 
2007). 
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For the divergent pulmonary phenotype, a huge amount of modifier genes has 
been described, with TGFB1 and MBL being the first ones that have been 
identified (reviewed in SHANTHIKUMAR et al., 2019). Transforming growth 
factor beta 1 (TGFB1), a major fibrogenic cytokine (GRAINGER et al., 1999), is 
one of the most widely examined potential gene modifiers in CF lung disease, as 
it plays a key role in the regulation of inflammation and tissue remodeling 
(AKHURST, 2004). Its impact on other lung disorders, such as asthma and 
chronic obstructive pulmonary disease (COPD), has already been described 
(PULLEYN et al., 2001; WU et al., 2004). Moreover, there is also evidence that 
interaction between TGFB1 genotype and tobacco smoke exposure additionally 
influences CF lung disease severity (COLLACO et al., 2008). Several studies on 
TGFB1 as a modifier of CF, including the large Gene Modifier Study (GMS), 
revealed, that a codon 10 CC genotype has been associated with enhanced 
expression of TGFB1, leading to increased inflammation and fibrosis, in turn 
resulting in more severe respiratory manifestation (DRUMM et al., 2005).  
The lack of mannose-binding lectin (MBL), a serum protein participating in innate 
immune response, is related to increased susceptibility to infections. (reviewed in 
TURNER, 2003). Consequently, as actually proved in a number of candidate 
modifier studies, a MBL-deficient genotype is suggested to be connected with 
worse clinical manifestation, characterized by higher infection rate and reduced 
lung function (reviewed in SHANTHIKUMAR et al., 2019). However, since the 
findings of numerous studies are in part contradictory, and the most robust study 
actually could not find any effect of MBL on lung disease diversity (DRUMM et 
al., 2005), the role of MBL as a modifier gene of CF still remains a matter of 
debate. 
Apart from TGFB1 and MBL, many other genes have been suggested as modifiers 
contributing to the diverse pulmonary phenotype in CF patients, such as 
homeostatic iron regulator (HFE) (REID et al., 2004; PRATAP et al., 2010; 
SMITH et al., 2019), endothelin receptor type A (EDNRA) (DARRAH et al., 
2010) and carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 
(STANKE et al., 2010). 
Moreover, current systematic GWAS identified five more regions that are 
correlated to lung disease severity (reviewed in O'NEAL & KNOWLES, 2018; 
SHANTHIKUMAR et al., 2019). On chromosome 3 mucin 4 (MUC4) and mucin 
20 (MUC20) have been detected, however, neither the region, nor the genes have 
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been identified in subsequent studies. In contrast, solute carrier family 9 member 
A3 (SLC9A3) on chromosome 5, as well as major histocompatibility complex 
(HLA) class II on chromosome 6 could both be detected as possible gene 
modifiers in additional investigations. The X chromosome revealed solute carrier 
family 6 member A14 (SLC6A14) to be associated with lung function and the risk 
of Pseudomonas aeruginosa infection. Further research detected ETS homologous 
factor (EHF) and APAF1 interacting protein (APIP) on chromosome 11 as 
potential gene modifiers. All hypothesized genes are of biological interest with 
high mechanistic probability (reviewed in O'NEAL & KNOWLES, 2018). 
However, it has to be mentioned that the loci of highest correlation are intergenic 
and hence very likely of regulatory function. Understanding the mechanistic effect 
of the suspected genes and expanding the present findings to even larger 
investigations will be an important challenge in future CF gene modifier research. 
 
3.2. Gene modifiers for the intestinal phenotype in Cystic Fibrosis 
Although the presentation of neonatal intestinal obstruction with meconium ileus 
(MI) is pathognomonic for Cystic Fibrosis (AGRONS et al., 1996), only 15-20 % 
of all CF infants are born with this characteristic trait. On the contrary, animal 
models for CF remarkably exhibit a more severe, but among each other, a still 
variable intestinal phenotype. In CF rats an intestinal obstruction at weaning is 
actually the most prominent feature (TUGGLE et al., 2014), whereas in CF mice 
the development of this trait usually depends on their genetic background 
(reviewed in FIOROTTO et al., 2019). CF ferrets are characterized by severe MI, 
appearing in approximately 75 % of all ferret kits (SUN et al., 2010). As a major 
drawback of the promising CF pig model, fatal MI even occurs with a penetrance 
of 100 % (KLYMIUK et al., 2012). While the respiratory phenotype is highly 
penetrant in CF patients, regardless of mutation class (DORFMAN et al., 2008), 
the occurrence of neonatal MI is usually associated with severe class I-III CFTR 
mutations in both alleles (KNOWLES & DRUMM, 2012; DUPUIS et al., 2016). 
Beyond that, studies in CF twins and siblings undoubtedly indicate a predominant 
impact of additional non-CFTR genetic modifiers on both, the contribution to and 
the protection against the occurrence of MI (BLACKMAN et al., 2006). In 
striking contrast to MI, the development of distal intestinal obstruction syndrome 
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(DIOS), a trait with clinical and pathologic similarities to MI in older CF patients, 
is not significantly influenced by modifier genes. 
The study of ROZMAHEL et al. (1996) initially described the role of further 
genetic factors on the intestinal disease in a murine model of CF, revealing a 
region on chromosome 7 to apparently influence intestinal obstruction. Examining 
the corresponding region of the human genome, located on chromosome 19, 
indeed indicated an association between variants in this region and the risk for MI 
(ZIELENSKI et al., 1999), but a causative gene has never been identified and also 
in later work this finding was not confirmed. (BLACKMAN et al., 2006). 
Genome-wide analyses revealed a few potential candidate loci, including 
polymorphisms in the genes coding for several members of the solute carrier 
family, either promoting (SLC6A14 on chromosome X, SLC9A3 on chromosome 
13, SLC26A9 on chromosome 1) or preventing the development of MI (SLC4A4 
on chromosome 4) (DORFMAN et al., 2009; SUN et al., 2012). Studies on 
murine models of CF clearly confirmed the protective effect of SLC4A4 variants 
against obstruction (GAWENIS et al., 2007). HENDERSON et al. (2012) 
confirmed an association between MSRA on chromosome 8, encoding for 
methionine sulfoxide reductase A, as CF mice lacking functional MSRA exhibit 
decreased incidence of intestinal obstruction in comparison to CF mice with 
functional MSRA. Another examination provided evidence for MI-promoting 
locus on chromosome 12 and suggested the involvement of the gene adiponectin 
receptor 2 (ADIPOR2) (DORFMAN et al., 2009). Just recently, two new potential 
modifier genes of MI have been identified, namely ATPase H+/K+ transporting 
non-gastric alpha2 subunit (ATP12A) on chromosome 13, and a suggestive locus 
on chromosome 7 near serine protease 1 (PRSS1) (GONG et al., 2019). 
For the porcine genome there are none potential modifiers that have been 
described so far, but the major contribution of additional non-CFTR genetic 
factors to neonatal intestinal obstruction in humans, as well as in murine models 
of CF, permits the assumption that also in CF pigs the severity of the intestinal 
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Aims of my thesis 
KLYMIUK et al. (2012) generated the first European CF pig model at the Chair 
for Molecular Animal Breeding and Biotechnology, LMU Munich, Germany. As 
the CF pig exhibit hallmark features of human CF disease, it turned out to be an 
indispensable model for different cooperation partners working on CF research. In 
order to regularly provide porcine tissue material to different partners, a CFTR 
breeding herd with heterozygous female and male CFTR+/- pigs has been 
established. Since an ever-present, severe intestinal phenotype with fatal MI 
constitutes the most prominent trait in CF piglets, the use of the pig as an animal 
model for CF is strongly limited. However, a previous thesis done at the Chair for 
Molecular Animal Breeding and Biotechnology describes the occurrence of three 
CF KO piglets (#2850, #3137 and #4424) that showed a clear improved intestinal 
phenotype (DMOCHEWITZ, 2016). In those piglets, the meconium has passed 
through the cecum and was stuck in middle to distal parts of the colon. Moreover, 
the CF-typical microcolon was not detectable, but the size and diameter of the 
colon was similar to a WT one. To clarify the relevance of the genetic background 
for this naturally occurring improvement, a genome-wide analysis has been 
performed. This SNP typing revealed, that there are two potential modifier loci on 
chromosome 10 (25.8–25.9 Mb) and on chromosome 16 (4.7–5.2 Mb), whereby 
the three rectified piglets were homozygous for a specific haplotype at both loci. It 
was therefore hypothesized that the severity of the intestinal phenotype might be 
improved in those CF piglets that show homozygosity for specific haplotypes on 
both chromosomes. Based on these findings, the aim of my thesis was to test the 
hypothesis of two independent loci on chromosomes 10 and 16 to protect CF 
piglets from MI. In the case the hypothesis was verified, the probability of an 
improved manifestation in CF piglets should be increased by enriching the 
frequency of the desired genotype on chromosomes 10 and 16 in the CF pig 
breeding herd. Eventually, an alternative evaluation of the genetic diversity was 
performed by genome-wide analysis on the basis of a larger population. 
Independently from the CF gut-phenotype, a variant respiratory phenotype was 
observed in some CF piglets during my thesis. 
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III. ANIMALS, MATERIALS AND METHODS 
1. Animals 
The animals included in this work were wild type (WT), heterozygous CFTR+/- 
and homozygous CFTR-/- (CFTR KO) piglets generated by selected breeding of 
heterozygous female and male CFTR+/-. All animal experiments were approved by 





Acetic Acid (glacial) Carl Roth, Karlsruhe, Germany 
Bromophenolblue Carl Roth 
Chloroform (Trichloromethane) Sigma-Aldrich, St. Louis, USA 
EDTA (Ethylenediaminetetraacetic acid) Carl Roth 
Ethanol Carl Roth 
GelRed® Nucleic Acid Gel Stain Biotium, Fremont, USA 
Glutardialdehyde solution 25 % Merck, Darmstadt, Germany  
Glycerin (Glycerol) Carl Roth and Sigma-Aldrich 
HCl (Hydrochloric acid) 1 mol/L Bernd Kraft GmbH, Duisburg, 
Germany 
Methanol Carl Roth 
MgCl2 (Magnesium chloride) Thermo Fisher Scientific, 
Waltham, USA 
NaOH (Sodium hydroxide 2N) Carl Roth 
Paraformaldehyde Sigma-Aldrich 
Perfadex® XVIVO Perfusion, Gothenburg, 
Sweden 
Sodium cacodylate trihydrate  Sigma-Aldrich 
Tris (Tris-(hydroxymethyl)-aminomethane) Carl Roth 
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TRIzol® Reagent Thermo Fisher Scientific 




Chyo Petit Balance MK-2000B YMC CO, Kyoto, Japan 
Eppendorf Centrifuge 5417 R Eppendorf, Hamburg, Germany 
Eppendorf Centrifuge 5424 Eppendorf 
Eppendorf Centrifuge 5910 R Eppendorf 
Gel documentation system Bio-Rad Laboratories, Hercules 
USA 
Grant JB Nova 5 water bath Grant Instruments Ltd, Royston, 
UK 
Hettich Rotina 380 R Andreas Hettich GmbH & Co. 
KG, Tuttlingen, Germany 
Incubator Memmert GmbH & Co. KG, 
Schwabach, Germany 
inoLab® pH meter 7110 WTW, Weilheim in 
Oberbayern, Germany 
Labcycler SensoQuest GmbH, Göttingen, 
Germany 
LightCycler® 96 Roche Diagnostics, Basel, 
Switzerland 
Mastercycler® gradient Eppendorf 
Microwave DAEWOO, Gangnam, South 
Korea 
OwlTM  EasyCastTM B1A and B2 Thermo Fisher Scientific 
Mini gel electrophoresis systems 
Pipettes (1000 µL, 200 µL, 20 µL, 10 µL, 2 µL) Gilson Inc, Middleton, USA 
Polytron homogenizer PT 2500 E Kinematica, Luzern, 
Switzerland  
Power Pac 300 gel electrophoresis unit Bio-Rad Laboratories 
Power Station 300 gel electrophoresis unit Labnet International, Edison, 
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USA  
RH Basic heating plate with magnetic stirrer IKA, Staufen im Breisgau, 
Germany 
Select vortexer Select BioProducts, Edison, 
USA 
SimpliNanoTM spectrophotometer Biochrom GmbH, Berlin; 
Germany 
Spectrafuge 24D Microcentrifuge Labnet International 
Thermo-Shaker TS-100 bioSan, Riga, Latvia 
Varioklav 400 autoclave H+P Labortechnik GmbH, 
Oberschleißheim, Germany 
 
2.3. Drugs, enzymes and oligonucleotides 
Drugs 
Altrenogest (Regumate®) MSD Animal Health, 
Unterschleißheim, Germany 
Azaperon (Stresnil®) Elanco Animal Health, Bad 
Homburg, Germany 
Choriongonadotropine (hCG) (Ovogest®) MSD Animal Health 
Cloprostenol (Estrumate®) MSD Animal Health 
Embutramid, Mebezonium, Tetracain (T61®) MSD Animal Health 
Ketamine hydrochloride (Ursotamin®) Serumwerk Bernburg AG, 
Bernburg, Germany 




BigDye® Terminator v3.1 Applied Biosystems, Foster 
City, USA 
DNase I, RNase-free (1 U/µL) Thermo Fisher Scientific 
FastStart Essential DNA Green Master Roche Diagnostics 
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Herculase II Fusion DNA Polymerase Agilent Technologies, Santa 
Clara, USA 
HotStarTaq Plus DNA Polymerase                        Qiagen, Hilden, Germany 
(5 U/µL) 
Proteinase K, ready to use Agilent Technologies 
SuperScriptTM III Reverse Transcriptase Thermo Fisher Scientific 
(200 U/µL) 
Qiagen® LongRange PCR Enzyme Mix Qiagen 
(5 U/µL) 
Uracil N-Glycosylase (UNG) (1 U/µL) Thermo Fisher Scientific 
 
Oligonucleotides 
All oligonucleotides were designed with the PrimerQuest Tool by IDT and were 
purchased from Thermo Fisher Scientific. 
 
Cg2f  5′ AGA AGA GTA GGG CCT TTG GCA T 3′ 
Cg1r  5′ TGG CTG AAC TGA GCG AAC AAG T 3′ 
Cg5r  5′ AGC ACA TGT GGG TCT TAG AGT ACG 3′ 
c105b1 5′ TGG AGC CTC AGG CTG AAA GCA 3′ 
c105g1 5′ CCT TGA AGA AGC TCT GCA ATA C 3′ 
c105g2  5′ CCT TGA AGA AGC TCT GCA AAA C 3′ 
c105g3 5′ CCT TGA AGA AGC TCT GCA AAT C 3′ 
c105g4 5′ CCT TGA AGA AGC TCT GCT ATA C 3′ 
c105g5 5′ CCT TGA AGA AGC TCT GCA ATT C 3′  
c105g6 5′ CCT TGA AGA AGC TCT GCA TTA C 3′ 
c105g7 5′ TGG AGC CTC AGG CTG AAA GCG 3′ 
c105g8 5′ TGG AGC CTC AGG CTG AAA CAG 3′ 
c167b1 5′ CAA GTT TAT GGT TCA GAG AAC CA 3′ 
c167g1 5′ CTT TAG AGT TAT AGA AGC TCA GC 3′ 
c167b2 5′ CAA GTT TAT GGT TCA GAG AAG CA 3 
c167b3 5′ CAA GTT TAT GGT TCA GAG ATG CA 3′ 
c169b1  5′ TCT ACT CTC AGG AAT GAG ATA CG 3′ 
c169g1 5′ TTG GGT CTC ATT CAT AAG GGG AT 3′ 
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c104f1  5′ GGG AGG AGG AGC CCT CAT AA 3′ 
c104r1  5′ GTG ATT GGT GCC TTG ACT GC 3′ 
c104f2  5′ CTG TGG CCC TGT CCC TTA TG 3′ 
c104r2  5′ TTG GTG CCT TGA CTG CCT AC 3′ 
c105f1  5′ AGT GCT AGG CAG CAA TGT GT 3′ 
c105r1  5′ GGC ATC AGA TGT CCA AGG CT 3′ 
c105f2  5′ CTA GCT CCC ATC CAC ACT GC 3′ 
c105r2  5′ AGC TTA GGG AGC CCA TGA GA 3′ 
c105f3  5′ TGT GAG GAC ATA TCC TCC 3′ 
c105r3  5′ CAT TGC CAT GGT GAG CAG C 3′ 
c167f1  5′ GGT AGC AGC TTC CCT GAT TT 3′ 
c167r1  5′ CTC TTG GTG TGG ATG CTA TCT T 3′ 
c167f2  5′ GTG GTT TCT TGG TGA GCT CTT A 3′ 
c167r2  5′ CCA TAA AGG GAG GCT TAG TGA TG 3′ 
c169f1  5′ CTA TCC CTG CCC TTG CTC AG 3′ 
c169r1  5′ CAA CCC CTA GTG TGG GAA CC 3′ 
c169f2  5′ CCC ATC ATG GCA CAG TAG TT 3′ 
c169r2  5′ CTT CCC ATT TCT TTG GGT ACT TTC 3′ 
c169f3  5′ TCA CAA ATT AGC ACA GTA CC 3′ 
c169r3  5′ TGT CTT AGT GAG TTC AGG C 3′ 
ch10f1  5′ GCC CTG CAT GAA TGA ATG ACC 3′ 
ch10r1  5′ TCT CGG AGT TCC CAC CAT GT 3′ 
ch10f2  5′ CTT TGC TGA CAG GGA CAC TCA 3′ 
ch10r2  5′ TGG AGG CAC GGG TTC AAT C 3′ 
ch10f3  5′ GAA TGA CCC AGA GAT GGA GAA G 3′ 
ch10r3  5′ AGA TGT GTG ATG GCA GGT AAA 3′ 
ch10f4  5′ ACA GCA ACA CCA GAT CCG AG 3′ 
ch10r4  5′ TGT GTG ATT GGG TCT TCG GG 3′ 
ch10f5  5′ TTA TGG GTG CAG AGC AGT GG 3′ 
ch10r5  5′ AGT CAG GCT CGT CCT GAG TA 3′ 
ch10f6  5′ ACA CCA GTG CCC AAA TAG AG 3′ 
ch10r6  5′ GAG AGA TGA CCC AAG CCA AAT A 3′ 
ch10s11 5′ CAC ACC CTA TTC CAC TAA G 3′ 
ch10s12 5′ GGA AAG AAT ATT GAG AAG TGC 3′ 
ch10s13 5′ TCT CTC TGT GAC TGA GAC AGC 3′ 
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ch10s14 5′ CTT GCA CAG AAC ACA GAG G 3′ 
ch10s21 5′ TGA CTT CAA GCT GTG TGA CC 3′ 
ch10s22 5′ AGC TGA TAA TAG TCT CTC C 3′ 
ch10s23 5′ GAT TTA CCA AGC TAG TGG AC 3′ 
ch10s24 5′ CGT CTT CCA ATA GAT TCC GC 3′ 
ch10s25 5′ TAC ACT AAT AAT GCC AGG 3′ 
ch10s61 5′ AAG ATA GCG TTT CTA GCA G 3′ 
ch10s62 5′ ATA AGC AGT TAA CCA TTG C 3′ 
ch10s63 5′ AGA TCA CCT GCT GCC CTG AG 3′ 
ch10s64 5′ CTC ACA GGC TGT TGT TCA G 3′ 
ch10s71 5′ AGC TGC CTT ATC AAG CTC TG 3′ 
ch10s72 5′ ATG CTG TTG TCG CAT GCC 3′ 
ch10s73 5′ TGG AGA GTC CTG TAA AGT GC 3′ 
ch10s74 5′ GAT CCT GCA TTC CTG TGA GC 3′ 
nek1f  5′ CTC TCA GTG CTA CAC AGG ATT T 3′ 
nek1r  5′ GCA ACC TCA TGG TTC CTA GTT 3′ 
nek2f  5′ CCA ACC GAA TCC AAC AAC ATA TC 3′ 
nek2r  5′ CTG TCA GAC CTC CAT TAT CAC C 3′ 
nek3f  5′ TGA GTC TAT CGC CCT CCC AA 3′ 
nek3r  5′ GGA ACA GAG GCA GTC TCC AC 3′ 
nek4f  5′ CTG GTG CGG TGT AAG GAA GT 3′ 
nek4r  5′ CTG TCG TGT CTC GCT GAA CT 3′ 
nek5f  5′ GGT CTT AGC ATT GCA GCT TTC 3′ 
nek5r  5′ ATA CGG GCT AAA GGT AGG TTT C 3′ 
nek6f  5′ GCA CAC ATT ACC CAA GGC 3′ 
nek6r  5′ GTA CAA TCA TGA GTA GAG C 3′ 
nek7f  5′ TGA ATT GAT ATG AGA AGC AG 3′ 
GAPqf1 5′ CAG AAC ATC ATC CCT GCT TC 3′ 
GAPqr1 5′ GCT TCA CCA CCT TCT TGA TG 3′ 
gapdhF1 5′ CAG CAA TGC CTC CTG TAC CA 3′ 
gapdhR1 5′ GAT GCC GAA GTT GTC ATG GA 3′ 
tbpF  5′ GAT GGA CGT TCG GTT TAG G 3′ 
tbpR  5′ AGC AGC ACA GTA CGA GCA A 3′ 
ywhazF 5′ ATG CAA CCA ACA CAT CCT ATC 3′ 
ywhazR 5′ GCA TTA TTA GCG TGC TGT CTT 3′ 
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Lars2f  5′ AAC CTG AAC AAG TTT GAT GAA G 3′ 
Lars2ra 5′ AAG GCA AGT CCA CAG AAG GC 3′ 
 
2.4. Buffers and solutions 
Water deionized in a Millipore device (BarnsteadTM EASYpureTM II, Wilhelm 
Werner GmbH, Leverkusen, Germany) and termed as aq. bidest. was used as 
solvent. All buffers and other solutions were stored at room temperature if not 
indicated otherwise 
 
Buffers and solutions for PCR and agarose gels 
DNA loading buffer (10×) 
10 % glycerol in aq. bidest. 
1 spatula tip of Bromophenol Blue 
Add 0.5 M NaOH until color turns blue 
Stored aliquoted at 4 °C. 
 
dNTP-mix 
2 mM dATP, dCTP, dGTP, dTTP 
Mixed in aq. bidest. 
Stored aliquoted at -20 °C. 
 
TAE buffer (50×) 
242 g 2 M Tris 
100 mL 0.5 M EDTA (pH 8.0) 
57 mL acetic acid (glacial) 
Ad 1000 mL aq. bidest. 
Buffer solution was filtrated and autoclaved for storage. 
Before usage the buffer solution was diluted to single concentration. 
 
Gene RulerTM 1 kb DNA 
100 µL Gene RulerTM 1 kb DNA 
100 µL 6x loading dye 
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400 µL aq. bidest. 
Stored aliquoted at -20 °C. 
 
Sequencing buffer (5×) 
17.5 mL 1 M Tris/HCl (pH 9.0) 
125 µL 1 M MgCl2 
Ad 50 mL aq. bidest. 
Stored aliquoted at -20 °C. 
 
Buffers and solutions for RNA isolation and cDNA synthesis 
10 mM Tris/HCl, pH 8.0 
10 mM Tris 
Adjust pH to 8.0 with HCl 
 
10 mM dNTPs 
10 mM dATP, dCTP, dGTP, dTTP 
Mixed in aq. bidest. 
Stored aliquoted at -20 °C. 
 
Buffers and solutions for fixation  
Methacarn 
60 % methanol 
30 % chloroform 
10 % acetic acid (glacial) 
Prepared freshly, stored in the dark. 
 
4 % PFA solution 
4 % PFA 
1× PBS buffer 
Solution was heated to 50 °C in a water bath and was vigorously shaken 
several times. For complete dissolution of PFA, 200 µL of 5 M NaOH 
were added to raise the pH. After cooling down to room temperature, the 
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solution was adjusted to pH 7.4 with HCl, filtered and stored at 4 °C. 
 
Modified Karnovsky fixative 
2 % PFA 
2.5 % of glutardialdehyde solution 25 % 
Mixed in 0.05 M sodium cacodylate buffer, pH 7.2 
Stored aliquoted at -20 °C. 
 
0.05 M sodium cacodylate buffer, pH 7.2 
Sodium cacodylate trihydrate  
Dissvoled in aq. bidest 
Adjust pH to 7.2 with HCl 
Stored aliquoted at -20 °C. 
 
2.5. Kits 
Double Pure Kombi Kit Bio&SELL 
Easy-DNATM Kit Invitrogen, Carlsbad, USA 
NexttecTM Genomic DNA Isolation Kit Nexttec Biotechnologie GmbH,  
From Tissue and Cells Leverkusen, Germany 
 
2.6. Other reagents 
0.1 M DTT Thermo Fisher Scientific 
10× CoralLoad PCR buffer Qiagen 
10× DNase reaction buffer with MgCl2 Thermo Fisher Scientific 
10× LongRange PCR Buffer Qiagen 
5× Herculase II Reaction Buffer Agilent Technologies 
5× Reaction Buffer for RT Thermo Fisher Scientific 
6× DNA loading dye Thermo Fisher Scientific 
dNTPs (dATP, dCTP, dGTP, dTTP) Thermo Fisher Scientific 
Gene RulerTM (1 kb DNA ladder) Thermo Fisher Scientific 
Oligo(dT)18 primer (0.5 µg/µL) Thermo Fisher Scientific 
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2.7. Software 
BioEdit Sequence Alignment Editor 
FinchTV Version 1.3.1, Geospiza Inc. 
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3. Methods 
3.1. Sampling of piglets 
Autopsy of piglets 
For molecular analyses and for experiments performed by cooperation partners, 
samples were taken from WT and CFTR-/- piglets. For this purpose, the piglets 
were anaesthetized i.m. with ketamine hydrochloride (2 mL/10 kg BW) and 
azaperone (0.5 mL/kg BW), followed by euthanasia via i.c. injection of 
Embutramid, Mebezonium, Tetracain (1 mL/10 kg BW). 
 
Preparation of the airways 
After euthanasia, the thorax was opened and, starting from the larynx, the 
connected trachea, the lungs and the heart were explanted. Then the heart, the 
esophagus, attached nerves and big blood vessels were removed. In pulmonary 
tissue the pH was measured for experiments on alternative airway chloride 
channels, performed by Karl Kunzelmann and Roberta Benedetto from the 
Institute for Physiology at the University of Regensburg. For experiments on 
mucociliary transport, performed by Anna Ermund from the Mucin Biology 
Group at the University of Gothenburg, Sweden, all pulmonary tissue was 
carefully pulled away with anatomical forceps until only the trachea and the 
bronchial tree were left. Meanwhile, the airways were repeatedly bathed in 
Perfadex® transport solution, which has been adjusted to pH 7.4 with 1 M Tris 
solution. For histopathological exploration, tracheal and bronchial tissue were put 
in 4 % PFA and immediately sent to Lars Mundhenk from the Institute of Animal 
Pathology at the Free University of Berlin, Germany. For scanning electron 
microscopy (SEM), the airways were fixed in modified Karnovsky fixative for 24 
hours. After transferring the samples to 0.05 M sodium cacodylate buffer, pH 7.2, 
they were sent to the Mucin Biology group in Gothenburg for further 
investigation. For RNA isolation purposes, tissue samples were cut into small 
pieces and quick-frozen on dry ice as fast as possible to prevent degradation. 
Samples were transferred to 1.5 mL Eppendorf tubes and stored at -80 °C until 
further examination. After the sampling of each tissue, the surgical instruments 
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were disinfected with 70 % ethanol to prevent contamination. The airways were 
photographed to document the phenotypical manifestation. 
 
Preparation of the intestine 
To document the severity of the intestinal phenotype, pictures were taken of the 
opened abdomen, the intestinal convolute in whole and the intestine laid out in 
full length. For histopathological examination tissue samples were collected from 
the pancreas, liver, gall bladder, different parts of the intestine (duodenum, 
jejunum, ileum, caecum, colon ascendens divided into gyri centripetales and gyri 
centrifugales, colon descendens and rectum), and in the case of male piglets also 
the testicles. For fixation, the tissue samples were put in either 4 % PFA or 
methacarn solution. Samples in methacarn fixative were stored in fridge, protected 
from light exposure, and transferred to 100 % methanol after approximately 48 
hours. For histological investigation PFA- and methacarn-fixed samples were sent 
to Lars Mundhenk from the Institute of Animal Pathology at the Free University 
of Berlin, Germany. 
 
3.2. Analysis at molecular level 
3.2.1. Genotyping of pigs 
Due to the fatal MI, health status of newborn CFTR-/- piglets deteriorates shortly 
after birth. Therefore, it was necessary to select relevant animals by fast 
genotyping, including fast isolation of DNA and time-saving genotyping 
Polymerase Chain Reaction (PCR). This was done for the CFTR genotype, as well 
as for the candidate regions on chromosomes 10 and 16 that presumably improve 
the intestinal phenotype. 
 
Isolation of genomic DNA  
From freshly cut tails of newborn piglets, genomic DNA was isolated using the 
nexttecTM Genomic DNA Isolation Kit from Tissue and Cells according to the 
manufacturer’s instructions. A small amount of tissue (5-30 mg) was transferred 
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to a 1,5 mL Eppendorf tube containing a lysis buffer, which is composed of three 
included components, and then incubated in a thermomixer with 1200 rpm at 
60 °C for at least 30 min. To ensure proper lysis of the tissue 3 µL DTT were 
added and the sample was vortexed vigorously several times during incubation 
time. The lysate was then transferred to an equilibrated cleaning column and 
centrifuged for 1 min at 700 rcf. The occurred eluate containing the purified DNA 
was immediately used for subsequent PCR.  
For genome-wide analysis, genomic DNA was isolated according to the 
manufacturer’s instructions described in “protocol #8 - isolation of DNA from 
mouse tails” from the Easy-DNATM Kit. The obtained DNA pellet was air dried 
for 6 minutes to remove residual ethanol and resuspended in 100 µL of 10 mM 
Tris/HCl, pH 8.0. The DNA concentration was finally diluted to 70 ng/µL. 
 
PCR 
A robust PCR for CFTR genotyping has been established in previous work 
(doctoral thesis of Michaela Désirée Dmochewitz, done at the Chair for Molecular 
Animal Breeding and Biotechnology, LMU Munich, Germany) and was used for 
genotyping each litter. Table 1 and Table 2 show the master mix composition and 
the cycler protocol. To rapidly identify the desired constellation at the candidate 
regions on chromosomes 10 and 16, PCRs for specific markers in the modifier 
loci were established and optimized. First, the proposed markers were confirmed 
by sequencing of amplified PCR products using primers indicated in Table 3. The 
applied master mix composition and the running conditions are shown in Table 4 
and Table 5. Then, marker-specific PCRs were developed for chosen sites, using 
one primer specifically binding to one of the marker variants and one unspecific 
primer (see Table 6). For each of the chosen sites, one PCR was established for 
each of the marker variants. PCRs were either conducted with the HotStarTaq 
Plus DNA Polymerase kit or with the Herculase II Fusion DNA Polymerase kit. 
The PCR components were mixed on ice to a final volume of 20 µL (HotStarTaq) 
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Table 1: Master mix composition for CFTR-genotyping PCRs. 
10× CoralLoad PCR buffer 2.0 µL 
dNTPs (2 mM) 2.0 µL 
Primer f (10 µM) 0.4 µL 
Primer r (10 µM) 0.4 µL 
HotStarTaq (5 U/µL) 0.2 µL 
aq. dest. 13 µL 
DNA template 2 µL 
 
Table 2: Cycler protocol for CFTR-genotyping PCRs. 
Denaturation 95 °C 5 min  
Denaturation 95 °C 20 s 
35× Annealing 56 °C 20 s 
Elongation 72 °C 30 s 
Final elongation 72 °C 5 min  
Termination 4 °C 5 min  
 
Table 3: Primers tested for amplification and sequencing of marker regions. 
c104f1 5′ GGG AGG AGG AGC CCT CAT AA 3′ 
c104r1 5′ GTG ATT GGT GCC TTG ACT GC 3′ 
c104f2 5′ CTG TGG CCC TGT CCC TTA TG 3′ 
c104r2 5′ TTG GTG CCT TGA CTG CCT AC 3′ 
c105f1 5′ AGT GCT AGG CAG CAA TGT GT 3′ 
c105r1 5′ GGC ATC AGA TGT CCA AGG CT 3′ 
c105f2 5′ CTA GCT CCC ATC CAC ACT GC 3′ 
c105r2 5′ AGC TTA GGG AGC CCA TGA GA 3′ 
c105f3 5′ TGT GAG GAC ATA TCC TCC 3′ 
c105r3 5′ CAT TGC CAT GGT GAG CAG C 3′ 
c167f1 5′ GGT AGC AGC TTC CCT GAT TT 3′ 
c167r1 5′ CTC TTG GTG TGG ATG CTA TCT T 3′ 
c167f2 5′ GTG GTT TCT TGG TGA GCT CTT A 3′ 
c167r2 5′ CCA TAA AGG GAG GCT TAG TGA TG 3′ 
c169f1 5′ CTA TCC CTG CCC TTG CTC AG 3′ 
c169r1 5′ CAA CCC CTA GTG TGG GAA CC 3′ 
c169f2 5′ CCC ATC ATG GCA CAG TAG TT 3′ 
c169r2 5′ CTT CCC ATT TCT TTG GGT ACT TTC 3′ 
c169f3 5′ TCA CAA ATT AGC ACA GTA CC 3′ 
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Table 4: Master mix composition for marker PCRs. 
5× Herculase II Reaction Buffer 5.0 µL 
dNTPs (2 mM) 2.5 µL 
Primer f (10 mM) 0.4 µL 
Primer r (10 mM) 0.4 µL 
Herculase II 0.2 µL 
aq. dest. 15.5 µL 
DNA template 1 µL 
 
Table 5: Cycler protocol for marker PCRs. 
Denaturation 95 °C 5 min  
Denaturation 94 °C 20 s 
35× Annealing 58 °C 20 s 
Elongation 72 °C 1 min 
Final elongation 72 °C 10 min  
Termination 4 °C 5 min  
 
Table 6: Primers tested for marker-specific genotyping PCRs. 
c105b1 5′ TGG AGC CTC AGG CTG AAA GCA 3′ 
c105g1 5′ CCT TGA AGA AGC TCT GCA ATA C 3′ 
c105g2 5′ CCT TGA AGA AGC TCT GCA AAA C 3′ 
c105g3 5′ CCT TGA AGA AGC TCT GCA AAT C 3′ 
c105g4 5′ CCT TGA AGA AGC TCT GCT ATA C 3′ 
c105g5 5′ CCT TGA AGA AGC TCT GCA ATT C 3′ 
c105g6 5′ CCT TGA AGA AGC TCT GCA TTA C 3′ 
c105g7 5′ TGG AGC CTC AGG CTG AAA GCG 3′ 
c105g8 5′ TGG AGC CTC AGG CTG AAA CAG 3′ 
c105f1 5′ AGT GCT AGG CAG CAA TGT GT 3′ 
c105r1 5′ GGC ATC AGA TGT CCA AGG CT 3′ 
c105f2 5′ CTA GCT CCC ATC CAC ACT GC 3′ 
c105r2 5′ AGC TTA GGG AGC CCA TGA GA 3′ 
c105f3 5′ TGT GAG GAC ATA TCC TCC 3′ 
c105r3 5′ CAT TGC CAT GGT GAG CAG C 3′ 
c167b1 5′ CAA GTT TAT GGT TCA GAG AAC CA 3′ 
c167g1 5′ CTT TAG AGT TAT AGA AGC TCA GC 3′ 
c167b2 5′ CAA GTT TAT GGT TCA GAG AAG CA 3′ 
c167b3 5′ CAA GTT TAT GGT TCA GAG ATG CA 3′ 
c167f1 5′ GGT AGC AGC TTC CCT GAT TT 3′ 
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c167r1 5′ CTC TTG GTG TGG ATG CTA TCT T 3′ 
c167f2 5′ GTG GTT TCT TGG TGA GCT CTT A 3′ 
c167r2 5′ CCA TAA AGG GAG GCT TAG TGA TG 3′ 
c169b1 5′ TCT ACT CTC AGG AAT GAG ATA CG 3′ 
c169g1 5′ TTG GGT CTC ATT CAT AAG GGG AT 3′ 
c169f1 5′ CTA TCC CTG CCC TTG CTC AG 3′ 
c169r1 5′ CAA CCC CTA GTG TGG GAA CC 3′ 
c169f2 5′ CCC ATC ATG GCA CAG TAG TT 3′ 
c169r2 5′ CTT CCC ATT TCT TTG GGT ACT TTC 3′ 
c169f3 5′ TCA CAA ATT AGC ACA GTA CC 3′ 
c169r3 5′ TGT CTT AGT GAG TTC AGG C 3′ 
 
Agarose gel electrophoresis 
For agarose gel electrophoresis, a 1 % agarose gel was produced by heating 1× 
TAE buffer with 1 g/100 mL Universal Agarose in a microwave till agarose 
completely dispersed. After cooling down to about 60 °C, GelRed® was added in 
a concentration of 5.0 µL/100 mL agarose gel and then the mixture was poured 
into an electrophoresis chamber. After solidifying, the chamber was filled with 1× 
TAE buffer as running buffer. PCR samples and 4.5 µL of Gene RulerTM 1 kb 
DNA were pipetted into individual gel slots. After separating in the electric field, 
DNA fragments were visualized under UV light. In order to verify a correct 
amplification of the PCR product, bands of the correct size were excised from the 
agarose gel, followed by elution and sequencing of the DNA. 
 
DNA-elution 
DNA was eluted according to the manufacturer’s instructions described in 
“protocol 1: isolation of DNA from agarose gels” from the Bio&Sell Double Pure 
Kombi Kit. To increase the final DNA yield, 30 µL of elution buffer, preheated to 
50 °C, were used. The successful extraction of the DNA was confirmed by mixing 
5 µL              eluted DNA  
2.5 µL           10× DNA loading buffer 
10 µL             aq. bidest. 
and loading this compound as well as 4.5 µL Gene RulerTM 1 kb DNA on 
prepared 1 % agarose gel. The eluted DNA was stored at -20 °C or immediately 
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used for following sequencing PCR. 
 
Sequencing PCR 
Sanger sequencing was performed with the BigDye® Terminator v3.1 Cycle 
Sequencing Kit. The master mix components (see Table 7) were mixed on ice to a 
final volume of 10 µL in 0.2 mL reaction tubes. Each DNA amplicon was 
sequenced either with the amplification and/or with internal sequencing primers. 
Table 8 indicates the running conditions for sequencing PCRs. 
 
Table 7: Master mix composition for sequencing PCRs. 
5× Sequencing buffer 4 µL 
BigDye® 1 µL 
Primer (10 µM) 1 µL 
DNA template 4 µL 
 
Table 8: Cycler protocol for sequencing PCRs. 
Denaturation 95 °C 1 min  
Denaturation 95 °C 5 s 
40× Annealing 54 °C 10 s 
Elongation 60 °C 4 min 
Termination 4 °C 15 min  
 
Purification of sequencing reactions  
Sequencing products were purified by ethanol precipitation. For this purpose, 2.5 
µL of 125 mM EDTA and 30 µL of 100 % EtOH were added to the amplified 
PCR. This mixture was then transferred to a fresh 1.5 mL Eppendorf tube and 
incubated on ice for 15 min. The samples were centrifuged at 13,000 rpm for 30 
min at 4 °C and the supernatant was carefully removed with a pipette. The pellet 
was washed in 150 µL of 70 % EtOH. After centrifugation at 13,000 rpm for 2.5 
min, the supernatant was removed again. The pellet was air-dried for 6 min, 
resuspended in 30 µL aq. dest. and finally transferred to a 96-well plate for 
capillary electrophoresis. The latter was performed at the Genome Analysis 
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Center, Helmholtz Zentrum Munich, Germany. Electropherograms were 
compared and evaluated with FinchTV Version 1.3.1 and the BioEdit Sequence 
Alignment Editor. 
 
3.2.2. Examination of candidate regions 
Within the candidate region on chromosome 10, three different genetic elements 
were investigated in more detail by sequencing of amplified PCR products. Table 
9 lists all primers that were tested for the amplification and sequencing of all three 
elements. PCRs were either conducted with the Herculase II Fusion DNA 
Polymerase kit or with the Qiagen® LongRange PCR kit. The optimal conditions 
for each PCR are presented in the results section. Amplified PCR products were 
sequenced via the Sanger approach following the same protocol as described 
under 3.2.1. “Genotyping of pigs” above. 
 
Table 9: Primers tested for amplification and sequencing of candidate region 
on chromosome 10. 
ch10f1 5′ GCC CTG CAT GAA TGA ATG ACC 3′ 
ch10r1 5′ TCT CGG AGT TCC CAC CAT GT 3′ 
ch10f2 5′ CTT TGC TGA CAG GGA CAC TCA 3′ 
ch10r2 5′ TGG AGG CAC GGG TTC AAT C 3′ 
ch10f3 5′ GAA TGA CCC AGA GAT GGA GAA G 3′ 
ch10r3 5′ AGA TGT GTG ATG GCA GGT AAA 3′ 
ch10f4 5′ ACA GCA ACA CCA GAT CCG AG 3′ 
ch10r4 5′ TGT GTG ATT GGG TCT TCG GG 3′ 
ch10f5 5′ TTA TGG GTG CAG AGC AGT GG 3′ 
ch10r5 5′ AGT CAG GCT CGT CCT GAG TA 3′ 
ch10f6 5′ ACA CCA GTG CCC AAA TAG AG 3′ 
ch10r6 5′ GAG AGA TGA CCC AAG CCA AAT A 3′ 
ch10s11 5′ CAC ACC CTA TTC CAC TAA G 3′ 
ch10s12 5′ GGA AAG AAT ATT GAG AAG TGC 3′ 
ch10s13 5′ TCT CTC TGT GAC TGA GAC AGC 3′ 
ch10s14 5′ CTT GCA CAG AAC ACA GAG G 3′ 
ch10s21 5′ TGA CTT CAA GCT GTG TGA CC 3′ 
ch10s22 5′ AGC TGA TAA TAG TCT CTC C 3′ 
ch10s23 5′ GAT TTA CCA AGC TAG TGG AC 3′ 
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ch10s24 5′ CGT CTT CCA ATA GAT TCC GC 3′ 
ch10s25 5′ TAC ACT AAT AAT GCC AGG 3′ 
ch10s61 5′ AAG ATA GCG TTT CTA GCA G 3′ 
ch10s62 5′ ATA AGC AGT TAA CCA TTG C 3′ 
ch10s63 5′ AGA TCA CCT GCT GCC CTG AG 3′ 
ch10s64 5′ CTC ACA GGC TGT TGT TCA G 3′ 
ch10s71 5′ AGC TGC CTT ATC AAG CTC TG 3′ 
ch10s72 5′ ATG CTG TTG TCG CAT GCC 3′ 
ch10s73 5′ TGG AGA GTC CTG TAA AGT GC 3′ 
ch10s74 5′ GAT CCT GCA TTC CTG TGA GC 3′ 
nek1f 5′ CTC TCA GTG CTA CAC AGG ATT T 3′ 
nek1r 5′ GCA ACC TCA TGG TTC CTA GTT 3′ 
nek2f 5′ CCA ACC GAA TCC AAC AAC ATA TC 3′ 
nek2r 5′ CTG TCA GAC CTC CAT TAT CAC C 3′ 
nek3f 5′ TGA GTC TAT CGC CCT CCC AA 3′ 
nek3r 5′ GGA ACA GAG GCA GTC TCC AC 3′ 
nek4f 5′ CTG GTG CGG TGT AAG GAA GT 3′ 
nek4r 5′ CTG TCG TGT CTC GCT GAA CT 3′ 
nek5f 5′ GGT CTT AGC ATT GCA GCT TTC 3′ 
nek5r 5′ ATA CGG GCT AAA GGT AGG TTT C 3′ 
nek6f 5′ GCA CAC ATT ACC CAA GGC 3′ 
nek6r 5′ GTA CAA TCA TGA GTA GAG C 3′ 
nek7f 5′ TGA ATT GAT ATG AGA AGC AG 3′ 
 
3.2.3. RT-PCR 
For expression analysis, RNA was isolated from porcine tissue samples and 
subsequently reversely transcribed into cDNA. CFTR expression was compared to 
the housekeeping genes GAPDH, TBP and YWHAZ. 
 
RNA isolation 
For isolation of tRNA from tissue samples stored at -80 °C, the acid guanidinium 
thiocyanate-phenol-chloroform extraction with TRIzol® was performed. To avoid 
possible RNase contamination all working steps were done under a separate hood. 
At first tissue was powdered in liquid nitrogen by using a hammer and mortar. 50-
100 mg of tissue powder was then transferred to a 2 mL Eppendorf tube filled 
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with 1 mL TRIzol® and immediately homogenized for 10 s at 30,000 rpm with the 
Polytron homogenizer PT 2500 E. After each sample, the grinder was cleaned 
carefully with aq. dest. for several times to avoid carry-over of contaminating 
material. After centrifugation at 12,000 rcf for 10 min at 4 °C, the clear 
supernatant was transferred to a new 1.5 mL Eppendorf tube and RNA was 
isolated according to the manufacturer’s protocol. RNA concentration was 
determined with a spectrophotometer by measuring the absorbance at a 
wavelength of 260 nm and 280 nm. Prepared and measured RNA samples were 
stored at -80 °C. 
 
DNase digestion 
In order to eliminate a possible contamination with genomic DNA (gDNA), RNA 
samples were treated with DNase I, RNase-free, an endonuclease that digests 
single- and double-stranded DNA. 
2 µL  10× reaction buffer with MgCl2 
1 µL  DNase I, RNase-free 
16 µL             aq. dest. 
1 µL  RNA (500 ng/µL) 
were mixed together and incubated for 30 min at room temperature. Afterwards   
1 µL of 25 mM EDTA was added to each sample and incubated at 65 °C for 10 
min to inactivate DNase. From each sample 10 µL were used for confirmation of 
complete DNA digestion. 
 
cDNA synthesis 
The residual 10 µL of the DNase digest were applied for first-strand cDNA 
synthesis, performed with SuperScriptTM III Reverse Transcriptase. cDNA 
synthesis was implemented according to the manufacturer’s instructions, whereby 
Oligo(dT)18 was used as primer. The obtained cDNA was stored at -20 °C until 
further processing. The integrity of the obtained cDNA was verified by 
amplification of the housekeeping gene GAPDH. The master mix composition as 
well as the running conditions for this PCR are shown in Table 10 and Table 11. 
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Table 10: Master mix composition for cDNA-verification PCRs. 
10× CoralLoad PCR buffer 2.0 µL 
dNTPs (2 mM) 2.0 µL 
Primer f (10 µM) 0.4 µL 
Primer r (10 µM) 0.4 µL 
HotStarTaq (5 U/µL) 0.1 µL 
aq. dest. 14.1 µL 
DNA template 1 µL 
 
Table 11: Cycler protocol for cDNA-verification PCRs. 
Denaturation 95 °C 5 min  
Denaturation 95 °C 20 s 
35× Annealing 58 °C 20 s 
Elongation 72 °C 45 s 
Final elongation 72 °C 5 min  
Termination 4 °C 5 min  
 
qPCR 
The CFTR expression in tissue samples of WT, CFTR-/- and respiratory improved 
CFTR-/- piglets was determined by comparing to housekeeping genes GAPDH, 
TBP and YWHAZ. Primers for different sets of qPCR have been tested in endpoint 
PCR in previous work (doctoral thesis of Michaela Désirée Dmochewitz, done at 
the Chair for Molecular Animal Breeding and Biotechnology, LMU Munich, 
Germany). My work was based on these conditions, but running conditions were 
optimized, whereby the optimal conditions are presented in the results section. 
The quality of each cDNA sample was tested by determining the amplification 
efficacy in a serial dilution with primers for GAPDH. For this purpose, five serial 
1:8 dilutions were prepared: 
1:8  10 µL cDNA      +     70 µL of 10 mM Tris/HCl, pH 8.0 
1:16  40 µL of 1:8 dilution     +     40 µL of 10 mM Tris/HCl, pH 8.0 
1:32  20 µL of 1:8 dilution     +     60 µL of 10 mM Tris/HCl, pH 8.0 
1:64  10 µL of 1:8 dilution     +     70 µL of 10 mM Tris/HCl, pH 8.0 
1:128  5 µL of 1:8 dilution     +     75 µL of 10 mM Tris/HCl, pH 8.0 
Each dilution was run in duplicates and a non-template control (NTC) served as a 
negative control. The qPCR master mix (see Table 12) was mixed on ice and 10 
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µL were used for each well in a LightCycler® 480 Multiwell Plate 96. Table 13 
indicates the running conditions for qPCR. The PCR efficacy was calculated by 
the LightCycler® 96 Application Software and cDNA showing improper 
amplification was excluded from further analysis and newly synthesized from 
DNase-digested RNA. Appropriate cDNA was used at the 1:16 dilutions and Ct-
values (threshold cycle) for CFTR, GAPDH, TBP and YWHAZ were determined in 
duplicates. Relative CFTR expression was calculated as Δ Ct-levels. 
 
Table 12: Master mix composition for qPCRs. 
FastStart Essential DNA Green Master 6.25 µL 
UNG 0.075 µL 
Primer f (10 µM) xx µL 
Primer r (10 µM) xx µL 
aq. bidest. ad 10 µL 
Template (cDNA) 2.5 µL 
 
Table 13: Cycler protocol for qPCRs. 
UNG activation 50 °C 2 min  
Denaturation 95 °C 10 min 
Denaturation 95 °C 10 s 
45× 
Annealing xx °C 90 s 
Melting 
95 °C 10 s  
65 °C 1 min 
97 °C 1 s 
Cooling 37 °C 30 s 
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IV. RESULTS 
1. The improved intestinal phenotype in CFTR-/- piglets 
The relevance of the genetic background for an improved intestinal phenotype 
was initially evaluated by a genome-wide survey of single nucleotide 
polymorphism (SNP) variations using the PorcineSNP60 DNA Analysis Kit v2 
(Illumina, San Diego, USA). SNP typing was implemented by Doris Seichter, 
Tierzuchtforschung e.V. München (TZF Grub, Germany) and data were analyzed 
by Sophie Rothammer and Ivica Medugorac, Population Genomics Group, 
Department of Veterinary Sciences, LMU Munich, Germany. This SNP typing 
revealed that there are two potential modifier loci on chromosome 10 (25.8–25.9 
Mb) and on chromosome 16 (4.7–5.2 Mb), whereby the three rectified piglets 
(#2850, #3137 and #4424) were homozygous for a specific haplotype at both loci. 
The findings are described in more detail in the doctoral thesis of Michaela 
Désirée Dmochewitz, done at the Chair for Molecular Animal Breeding and 
Biotechnology, LMU Munich, Germany. First goal of my thesis was to check the 
hypothesis of two modifying loci on chromosomes 10 and 16. For this, it was 
necessary to increase the frequency of the desired genotype constellation in the 
breeding herd and then to produce the CF piglets with this constellation at larger 
scale. All available pigs of the breeding herd were screened for the potential 
modifier loci on chromosome 10 and on chromosome 16. Marker-specific 
genotyping-PCRs were established to rapidly identify the desired genotype 
constellation.  
 
1.1. Evaluation of candidate regions on chromosomes 10 and 16 
1.1.1. Marker-based selection of breeding animals 
The desired haplotype constellation on chromosome 10 was covered by 6 marker 
positions and on chromosome 16 by 10 marker positions. To avoid costly and 
time-consuming SNP-typing for each breeding animal and each CF piglet, I aimed 
at establishing marker-specific PCRs that discriminate the desired haplotype “g/g” 
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from any of the non-desired constellations. Via genome-wide association study 
(GWAS) the three CF KO piglets with the improved intestinal phenotype were 
compared to all CF KO littermates as well as with any parents and grandparents 
for which samples were available. For the two candidate loci on chromosome 10 
and on chromosome 16 all haplotype patterns were compared (see Figure 1). In 
both cases only one specific haplotype (haplotype 1) is postulated to be beneficial 
for the manifestation of an improved intestinal phenotype in CFTR-/- piglets, all 
other haplotypes are presumably unfavorable. To distinguish the desired 
haplotype from unwanted ones with a minimal effort, markers on positions 1, 4, 5 
or 6 for chromosome 10 and markers on positions 7 and 9 for chromosome 16 
must be applied. All potential markers were examined in the context of the 
porcine reference genome; marker 4 on chromosome 10 turned out to be an 
artefact, whereas the other positions were identified in the reference genome. We 
decided to use marker 5 as indicative for chromosome 10 and a combination of 
markers 7 and 9 as indicative for chromosome 16. Each of these indicative 
markers is evaluated for both allele variants. If both alleles on the marker position 
correspond to the desired variant, the haplotype is “g/g” (g = good), whereas the 
haplotype is “g/b” (b = bad) or “b/b”, if one or none allele is congruent. 
At first the markers were confirmed by sequencing of amplified PCR products. 
For this purpose, two different primer pairs were tested for amplification of each 
marker sequence under standard conditions (see Table 4 and Table 5 in III., 
3.2.1.). For each marker we chose the better of the two primer pairs, excised the 
band from the gel and verified the nucleotide sequence (see Figure 2). Each 
sample was sequenced independently with a forward and/or a reverse primer. On 
the basis of the verified marker positions, SNP-specific primer pairs were 
designed. To increase the probability of the desired haplotype constellation in CF 
piglets, all animals of the existing breeding herd were screened for the candidate 
regions on chromosome 10 and on chromosome 16 (see Figure 3) and selected for 
breeding according to their haplotype. 
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Figure 1: Distinguishing the desired haplotype from unwanted ones by 
detecting informative markers. Marker 5 on chromosome 10 and markers 7 and 9 
on chromosome 16 are suitable SNPs to differentiate the desired haplotype 
(haplotype 1) from all others. As marker 4 (marked gray) on chromosome 10 turned 
out to be an artefact, it was not taken into further consideration. The haplotypes are 
described as “g/g”, “g/b” or “b/b” depending on whether both, only one or none of 
the two alleles comply with the wanted haplotype. The three intestinal improved 
piglets (#2850, #3137 and #4424) show homozygosity for the desired haplotype at 
both candidate loci. 
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Figure 2: Exemplary electropherograms of the marker regions. An animal’s 
haplotype is discriminated by SNPs (marked blue) with the help of marker-specific 
primer pairs, whereby the sequence of the primer pairs is indicated in the upper 
lines (see chapter IV.1.1.2.). It should be noted that no single individual showed a 
“g/b” constellation on marker c167, wherefore no electropherogram for the 
heterozygous constellation is shown.  
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Figure 3: Haplotypes of the initial breeding herd. Marker c105 was indicative 
for the desired candidate region alone, while for chromosome 16 the “g” 
constellation only on both, the c167 and the c169 marker, suggested the desired 
haplotype.  
  
1.1.2. Establishment of marker-specific genotyping PCRs 
Since sequencing of marker regions is very time-consuming, marker-specific 
genotyping-PCRs were established to rapidly identify the desired genetic 
constellation at both candidate regions. For each marker on chromosome 16, 
marker 7 and marker 9, two individual PCRs were designed. One PCR identifies 
the desired (“g”) haplotype, the second one detects the undesired (“b”) 
constellation. For marker 5 on chromosome 10 only one PCR was established that 
ruled out any unwanted haplotype. To establish robust PCRs, various sets of SNP-
specific primer pairs as well as different master mix compositions were tested. 
Table 14 and Table 15 demonstrate the final conditions for each discrimination 
PCR. Genotyping by marker-specific PCRs and Sanger sequencing gave 
consistent results (see Figure 4). 
While on chromosome 10 the desired haplotype “g/g” was abundant at high 
frequency, the desired haplotype on chromosome 16 was low and almost extinct 
in female animals (see Figure 3 above). However, in a parallel attempt on 
reducing inbreeding by mating with unrelated WT animals, a higher frequency of 
the desired haplotype was achieved (see Figure 5 and Figure 6). 
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Table 14: Final master mix compositions for discrimination PCRs. 
Marker Primer pair * MgCl2 HotStarTaq DNA template 
c105-b c105b1/c105r3 0.0 µL 0.1 µL 1 µL 
c167-b c167b3/c167r2 0.0 µL 0.1 µL 2 µL 
c167-g c167f1/c167g1 2.0 µL 0.2 µL 1 µL 
c169-b c169b1/c169r3 0.0 µL 0.2 µL 1 µL 
c169-g c169f2/c169g1 0.0 µL 0.1 µL 1 µL 
* 0.4 µL of 10 µM stock solution was applied for each primer.  
Table 15: Cycler protocol for discrimination PCRs. 
Denaturation 95 °C 5 min  
Denaturation 94 °C 20 s 
35× Annealing 58 °C 20 s 
Elongation 72 °C 1 min 
Final elongation 72 °C 10 min  
Termination 4 °C 5 min  
 
 
Figure 4: Confirming the sequenced haplotypes of the initial breeding herd by 
marker-specific discrimination PCRs. To identify the haplotype of each marker, 
the separate PCRs are considered in combination. The detection of a single band in 
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the “b”- or “g”-PCR only, defines the “g/g” or the “b/b” constellation. If there are 
bands in both PCRs detectable, the “g/b” haplotype exists. 
 
 
Figure 5: Haplotypes of the additional breeding animals. Heterozygous CFTR+/- 
sows of the initial breeding herd were inseminated with sperm of WT boars to 
generate further CFTR+/- pigs as potential new breeding animals. 
 
 
Figure 6: Discrimination of the additional breeding animals by marker-
specific discrimination PCRs. 
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1.1.3. CFTR-/- piglets with the desired genotype constellation 
Outbreeding delivered new heterozygous CFTR+/- pigs with an increased 
frequency of the desired haplotypes. Animals with homozygous “g/g” on 
chromosome 10 and heterozygous “g/b” on chromosome 16 were raised and 
mated to have a higher probability of the desired haplotype combination in the CF 
offspring. 
Immediately after birth, all piglets were evaluated by genotyping PCRs for CFTR 
as well as for the markers c105, c167 and c169. CF KO piglets were euthanized 
and examined for their intestinal phenotype. During a period from February to 
December 2018, marker-specific genotyping PCRs revealed 10 out of 55 CFTR-/- 
piglets in 19 litters that showed homozygosity for the desired haplotype at both 
candidate regions. Genotyping and pedigree of an exemplary CFTR litter is shown 
in Figure 7 and Figure 8. None of the CFTR-/- animals showed autonomous release 
of meconium. This is confirmed by the macroscopic and histological examination 
of the CF piglet #6491 which exhibited the desired genotype constellation on 
chromosome 10 and on chromosome 16 in comparison to the CF piglet #6345 
which lacked the desired genotype constellation (see Figure 9 to Figure 11). 
Obviously, there was no phenotypic difference between the animals. The distinct 
localization of the intestinal obstruction reflected the typical variation seen in CF 
piglets. In sum, all CF KO piglets with the desired genotype on chromosome 10 
and on chromosome 16, showed an MI similar to normal CF KO piglets. The 
naturally occurring improvement of the intestinal phenotype found in the 
previously described animals (#2850, #3137 and #4424), could not be replicated 
by selected breeding for the proposed modifier loci. The hypothesis of the 
beneficial influence of these loci was therefore clearly rejected. 
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Figure 7: Marker-specific discrimination PCRs performed in an exemplary 
CFTR litter. The CFTR-/- piglets #6192 and #6198 (marked green) are 
homozygous for the desired haplotype at all markers. Previously discriminated 
animals served as controls.   
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Figure 8: Pedigree of promising CFTR-/- piglets from an exemplary CFTR 
litter. Green constitutes WT pigs, heterozygous CFTR+/- breeding animals are 
represented in blue and red remarks CFTR-/- piglets. Boxes stand for male pigs; 
females are indicated by circles. The promising genetic structure found in the CF 
KO piglets #6192 and #6198 was attained over two generations by outbreeding and 
particular mating of heterozygous CFTR+/- animals. 
 
 
Figure 9: Pedigree of CFTR-/- piglet #6491 with the desired genotype. Based on 
the promising CF piglet #6491, the expression of the intestinal phenotype was 
exemplary investigated by comparing with a normal CF KO piglet that did not 
demonstrate the desired genetic constellation in previously implemented 
discrimination PCRs.   
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Figure 10: Intestinal phenotype of the promising CFTR-/- piglet #6491 
compared with a normal CFTR-/- piglet #6345. (A) View of the intestinal 
convolute after opening the abdomen. (B) and (C) The intestinal convolute after 
resection. White asterisks mark the presence of meconium. Black arrows point to 
the colon, the cecum is marked by discontinuous black arrows. A severe MI is 
present in both animals. In piglet #6491 the cecum and the colon ascendens are 
severely enlarged by stuck meconium. The reduced diameter of the following colon 
descendens is similar to the CF-typical microcolon apparent in piglet #6345. The 
severity of the intestinal phenotype is comparable in both the CF KO piglet 
exhibiting the desired genotype and the CF piglet without the special constellation. 
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Figure 11: Histopathological examination of intestinal tissue in the promising 
CFTR-/- piglet #6491 compared with a normal CFTR-/- piglet #6345. (A) PAS-
staining of 4 % PFA- (#6491) and methacarn-fixed (#6345) duodenal tissue. (B) 
PAS-staining of 4 % PFA-fixed colon ascendens (#6491) and colon descendens 
(#6345). (C) PAS-staining of methacarn-fixed colon ascendens (#6491) and 4 % 
PFA-fixed colon descendens (#6345). In both animals, duodenal Brunner’s glands 
(A), as well as crypts in the colon (B) are severely dilated and filled with mucus. 
The colon itself (C) is stuffed with large amounts of mucous material, whereby in 
piglet #6345 the additional CF-typical microcolon with reduced diameter is 
apparent (data kindly provided by Lars Mundhenk from the Institute of Animal 
Pathology at the Free University of Berlin, Germany). 
 
1.1.4. Detailed examination of the candidate region on 
chromosome 10 
The postulated candidate region on chromosome 10 (25.8–25.9 Mb) was defined 
by a specific pattern of 6 marker positions. Within this region, there was no 
annotated genetic element in the Sscrofa 10.2 reference genome. A multi-species 
alignment of chromosome 10 however revealed two loci within the candidate 
region that are characterized by high homology among different species, are 
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covered by bioinformatically predicted genetic elements and are consistent with 
potential regulatory function by the PreMod algorithm (Figure 12). Further, the 
last exon of NIMA related kinase 7 (NEK7) was located outside the region 
covered by the markers, but situated inside the nearest up-stream marker. 




Figure 12: Multi-species alignment of chromosome 10. In a multi-species 
alignment, the similarity among genomic sequences of different species is studied. 
Shared patterns with possible regulatory or functional relevance can thus be 
identified. The performed alignment detected two loci that are highly homologous 
among the species. The PreMod database suggested a potential regulatory function 
of this loci and the GeneScan tool predicted them to be part of not clearly specified 
genetic elements. 
 
All three regions were investigated by sequencing of PCR products amplified 
from CF pigs with a g/g, g/b or b/b haplotype, as determined by Sanger 
sequencing of the marker site c105 (see chapter IV.1.1.1.). Standard conditions, 
according to Table 12 and Table 13, proved sufficient for PCR amplification of 
locus 1 and locus 2 (see Figure 13). For amplifying locus 3, several primer pairs 
were tested (see Figure 14). Finally, the primers nek3f and nek2r used in an 
optimized master mix composition and cycler protocol, resulted in efficient 
amplification (Table 16 and Table 17). Overall six animals with different c105 
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haplotypes were explored: two animals exhibiting the g/g constellation, three 
animals with the g/b haplotype and one b/b individual. Sequencing of PCR 
products was performed with amplification and internal sequencing primers. By 
comparing the PCR amplicons, SNPs were found in locus 1 and locus 2. Locus 1 
revealed six SNPs and in locus 2 seven SNPs were identified. Examination of 
locus 3 did not reveal any polymorphisms between the different c105 haplotypes 
(see Figure 15 A). As the patterns of SNPs in locus 1 and locus 2 were not 
consistent with the marker-defined haplotypes, none of the identified 
polymorphisms could present a causative mutation that supports the initial 
hypothesis of a modifier region on chromosome 10 (see Figure 15 B, Figure 16 
and Figure 17). This finding correlated to the rejection of the hypothesis by 
selected breeding (see chapter IV.1.1.3.). A further examination of the second 




Figure 13: Amplification of locus 1 and locus 2 in exemplary CFTR animals. 
After testing different primer pairs, the most promising ones (primer pair 1 for 
locus 1 and primer pair 2 for locus 2) were optimized. Under UV-light, amplified 
PCR products of the correct size were cut out of the agarose gel, DNA was eluted 
and subsequently used for sequencing reaction. 
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Figure 14: Amplification of locus 3 in exemplary CFTR animals. (1-3) Testing 
of primer pairs for amplification of locus 3. Primer pairs were tested with the 
Herculase II Fusion DNA Polymerase kit with a volume of 0.4 µL each. Primer 
pairs 2 and 3 were selected for further optimization by different combination of the 
primers. (4) Final amplification of locus 3 with the primer pair nek3f / nek2r by 
using the Qiagen® LongRange PCR kit. Bands of the correct bp size were cut out of 
the gel and eluted DNA was applied in following sequencing reaction. 
 
Table 16: Master mix composition for locus 3-PCR. 
10× LongRange PCR Buffer 2.5 µL 
dNTPs (10 mM) 1.25 µL 
Primer f (10 µM) 0.5 µL 
Primer r (10 µM) 0.5 µL 
LongRange (5 U/µL) 0.2 µL 
aq. dest. 18.05 µL 
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Table 17: Cycler protocol for locus 3-PCR. 
Denaturation 93 °C 3 min  
Denaturation 93 °C 15 s 
35× Annealing 62 °C 30 s 
Elongation 68 °C 3.5 min 
Termination 4 °C 15 min  
 
 
Figure 15: Evaluation of SNPs in the candidate region of chromosome 10. (A) 
Identified SNPs in the three specified loci. SNPs were found in locus 1 and locus 2, 
with their position relative to the 5′-end of the forward primer indicated. In locus 1 
six SNPs were identified and locus 2 revealed seven possible SNPs. Investigating 
locus 3 did not detect any polymorphisms between the examined animals. (B) 
Overview of all examined SNPs in two individuals with the g/g constellation, three 
animals with the g/b haplotype and one individual exhibiting the b/b constellation. 
Regarding the latter, we identified only one single animal in our herd with the 
specific genotype. As the identified SNPs in locus 1 and locus 2 were not consistent 
with the marker-defined haplotypes, none of these polymorphisms could present a 
causative mutation according to the initial hypothesis of a modifier region on 
chromosome 10. 
 




Figure 16: SNP patterns in locus 1. For each SNP, representative 
electropherograms from pigs with marker constellations g/g, g/b or b/b are shown. 
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Figure 17: SNP patterns in locus 2. For each SNP, representative 
electropherograms from pigs with marker constellations g/g, g/b or b/b are shown. 
The position of the SNP is highlighted by a blue box. 
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1.2. Novel genome-wide analysis 
Although the initial hypothesis of two modifying loci on chromosome 10 and on 
chromosome 16 was fully rejected and no additional piglet with an improved gut-
phenotype was born, the close familial relation of these animals suggested an 
influencing effect by the genetic background. Therefore, we performed an 
alternative analysis based on a combined linkage disequilibrium and linkage 
analysis (cLDLA) (MÜLLER et al., 2017) on the basis of a more extended 
population of animals. This included all initial 146 CFTR-/- piglets, three of them 
with the gut improved phenotype, and 50 heterozygous CFTR+/- breeding animals 
as well as 55 additional CFTR-/- animals that were born between February and 
December 2018 as well as 14 new breeding animals that were involved in the 
extended pedigree. The animals were investigated using the PorcineSNP60 DNA 
Analysis Kit v2 (Illumina, San Diego, USA). SNP typing was performed by Doris 
Seichter, Tierzuchtforschung e.V. München (TZF Grub, Germany) and data were 
analyzed by Ivica Medugorac, Population Genomics Group, Department of 
Veterinary Sciences, LMU Munich, Germany. The newly obtained data were 
combined with the data set from the previous analysis.  
As in human CF patients the variability of the intestinal phenotype is proven to be 
dependent on modifying loci, the regions covering the proposed modifier genes 
SLC6A1 (AHMADI et al., 2018), SLC26A9 (LIU et al., 2015), SLC9A3 (LI et al., 
2014), ZG16 (BERGSTROM et al., 2016), CLCA1 (VAN DER DOEF et al., 
2010), MSRA (HENDERSON et al., 2012), ADIPOR2 (DORFMAN et al., 2009) 
and GUCY2C (ARORA et al., 2017) have been investigated regarding their 
relevance in porcine CF. A detailed examination indicated that none of these 
human modifiers were involved in similarly modulating CF in pigs (see Figure 
18). Instead, cLDLA revealed two significant peaks on chromosome 5 and on 
chromosome 13 that have been studied in more detail (see Figure 19).  
The candidate region on chromosome 5 is spanning over a segment of 1.5 Mb 
according to the Sscrofa 10.2 reference genome and corresponding to the regions 
chr12p13.33 and chr2q11.21 in the human genome. The locus is indicated by two 
sharp, closely adjacent peaks and contains 12 genes (see Figure 19 A). Haplotype 
analysis suggested a heterozygous influence of three haplotypes, narrowing the 
candidate region down to a size of 1.13 Mb covered by five markers. This 
genomic sequence covers a number of genes in all examined animals, including 
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ATP6V1E1 located within the center of the candidate region. The encoded protein 
of this gene is a component of the multi-unit vacuolar ATPase, a proton pump 
acting on the acidification of intracellular organelles and extracellular 
compartments (MCGUIRE et al., 2017). The abundance of other genes or genetic 
elements in the gut was low or almost absent (NCBI) or the submitted function 
described in the literature or the OMIM database give only little hint for an 
involvement in compensating lacking CFTR. 
Examination of the candidate region on chromosome 13 revealed a segment of 
0.41 Mb. This region corresponds to the human chr3p24.1, is indicated by a broad 
single peak and comprises only four genes (see Figure 19 B). Haplotype analysis 
presumes the involvement of a small region covered by only three markers, 
narrowing the candidate region down to 180 kb. The suggested region resembles 
the upstream region of TGFBR2, a gene that is expressed in almost any tissue 
(NCBI). Its protein is well known for its diverse roles in cell proliferation, 
including the continuous turnover of epithelial cells in the gut (FLENTJAR et al., 
2007; ZHANG et al., 2016). 
Is has to be mentioned that cLDLA analysis revealed further peaks apart from the 
investigated candidate regions, but none of them reached a peak level of similar 
height as the suggested modifying loci on chromosomes 5 and 13. Nonetheless, 
the new hypothesis has to be verified in future studies, whereby a more detailed 
characterization of the submitted modifier genes ATP6V1E1 and TGFBR2 is 
indispensable. The described data are part of a manuscript in preparation. 
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Figure 18: Combined linkage disequilibrium and linkage analysis (cLDLA) of 
intestinal improved CFTR-/- piglets compared with normal CFTR-/- piglets. 
Detailed examination of the proposed modifier genes of the gut-phenotype in 
human CF patients indicated that none of the candidate loci ZG16, CLCA1, 
GUCY2C, ADIPOR2, SLC26A9, MSRA or SLC6A14 is relevant in porcine CF. For 
each locus, the likelihood-ratio test (LRT) values, illustrated by blue dots, are 
indicated for the respective gene, presented in green, plus 10 LRT sites up- and 
downstream. The position of genes in the respective loci were taken from the 
Sscrofa 10.2 reference genome, after correlating to the corresponding genomic 
regions in the human reference genome. The corresponding genomic locations in 
the human genome are indicated for each locus. The y-axis (LRT value) is at the 
same scale for each locus. 
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Figure 19: Further examination of new candidate regions on chromosomes 5 
and 13. (A) Analysis of candidate region on chromosome 5. The locus on 
chromosome 5 is indicated by two sharp, closely adjacent peaks and is packed by 
genes (upper illustration). Haplotype analysis suggests a heterozygous constellation 
of a region covered by five markers (marked orange). This genomic segment covers 
a number of genes in all examined animals, including ATP6V1E1. (B) Examination 
of candidate region on chromosome 13. The locus on chromosome 13 is indicated 
by a broad single peak and covers only few genes. Haplotype analysis suggests the 
involvement of a small region covered by only three markers (marked orange) 
which resembles the upstream region of TGFBR2. 
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2. The improved respiratory phenotype in CFTR-/- piglets 
During my thesis, the routine breeding program continued and overall, a number 
of 119 CF piglets has been produced. While we did not observe any further piglets 
with a modified phenotype of the gut, we found in total five CF piglets (#5703, 
#5704, #5786, #6046, #6704) that showed morphological changes in the airways 
at the time of examination. Those piglets exhibited a WT-like round trachea with 
a greater diameter in comparison to a typically triangular-shaped trachea with 
reduced diameter in all other CFTR-/- piglets. 
 
2.1. Finding genetic causes for the improved respiratory phenotype  
During routine section it became obvious that initially three animals (#5703, 
#5704, #5786) differed from normal CF piglets in their trachea by presenting a 
WT-like round caliber with greater diameter, while their genotype and also a 
significant MI clearly indicated common signs of CF. Experiments on mucociliary 
clearance, done by Anna Ermund from the Mucin Biology Group at the 
University of Gothenburg, Sweden, demonstrated a mucus bundle velocity which 
is at least as fast as in a WT trachea. To clarify a potential involvement of the 
genetic background in the naturally occurred modification of the CF airways, the 
parental animals of improved piglets (boar #5081, sow #5373) have been mated 
systematically (see Table 18). In this manner, we succeed in reproducing the 
modified phenotype in two more piglets (#6046, #6704). For a precise description 
of the origin of the respiratory improved piglets and their parents in the context of 
the entire CFTR breeding herd, a pedigree containing all the ancestors and 
littermates was created (see Figure 20). The close familial relation of all airway-
improved animals and the reproduction of the phenotype by selected breeding, 
suggested an influence of modifier genes. 
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Table 18: Overview of all respiratory improved CFTR-/- piglets. 
Boar # Sow # CF KOs # Phenotype 
5081 3506 5703 respiratory improved 
  5704 respiratory improved 
5081 5373 5786 respiratory improved 
  5788 normal CF KO 
  5790 normal CF KO 
5081 5373 6046 respiratory improved 
  6051 normal CF KO 
  6056 normal CF KO 
5081 5373 6438 normal CF KO 
5081 5373 6702 normal CF KO 
  6704 respiratory improved 
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Figure 20: Pedigree of the CFTR breeding herd. WT pigs are represented in 
green, blue constitutes heterozygous CFTR+/- breeding animals and red remarks 
CFTR-/- piglets. Males are indicated by boxes; circles stand for female pigs. CF 
piglets of both sexes are symbolized by combined boxes and circles. All respiratory 
improved piglets #5703, 5704, 5786 and 6046, highlighted in dark red, descends 
from one single boar #5081 and two different sows, #3506 and #5373. 
 
2.2. Macroscopic examination of the improved respiratory phenotype 
Macroscopically, the airway-modified phenotype is characterized by a WT-like 
trachea with an almost round caliber and a greater diameter in comparison to the 
CF-typical triangular trachea with clearly reduced diameter (see Figure 21). Is has 
to be mentioned that in some cases the modification did not extend regularly over 
the total length of the trachea, but only partially in the middle part, whereas the 
sections close to the larynx and the main bronchi branching off the trachea, 
showed CF-typical features. Nevertheless, in all cases of modification, the overall 
trachea appeared to be less fragile than the tender structure of a CF-trachea, 
whereby a WT-trachea is even more robust. Apart from the improved respiratory 
phenotype, all other characteristic features of CF, including a severe intestinal 
obstruction by MI as well as a micro-gallbladder, were still present. 
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Figure 21: The improved respiratory phenotype (#6046) compared with a 
normal CFTR-/- piglet (#6051) and a WT piglet (#6138). (A) The airways after 
resection. In comparison to the triangular shaped trachea with clearly reduced 
diameter in a normal CF pig, the trachea of the respiratory improved CF piglet 
showed a WT-like round caliber with greater diameter. (B) The intestinal convolute 
after opening the abdomen. White asterisks mark the presence of meconium. In 
contrast to the changes in the respiratory tract, the intestinal phenotype of piglet 
#6046 was typical for CF. 
 
2.3. Detailed examination of the improved respiratory phenotype  
To initially verify a lack of CFTR expression in respiratory modified CFTR-/- 
piglets, a quantitative PCR (qPCR) was performed. By comparing to 
housekeeping genes, the relative quantification of CFTR expression in pulmonary 
tissue of two respiratory improved CF piglets (#5786, #6046), two normal CF pigs 
(#5788, #6051) and one WT piglet (#6138) was determined (see Figure 22). The 
optimal conditions for the established qPCRs are presented in Table 19. Since the 
expression of housekeeping genes varies also within the same tissue material, we 
chose three different genes, GAPDH, TBP and YWHAZ, in order to exclude 
artifacts. qPCR revealed that, although there is a certain variance, the 
housekeeping genes are generally expressed in all examined animals. However, an 
expression of CFTR was only detectable in the WT control. Normal CF piglets as 
well as the airway-improved piglets lacked expression of CFTR. 
A histopathological exploration was performed by Lars Mundhenk from the 
Institute of Animal Pathology at the Free University of Berlin, Germany. By 
comparing the bronchus trachealis of a modified piglet with a normal CF piglet, 
the greater diameter in the case of the improved animal was clearly apparent (see 
Figure 23). For a further examination of the improved respiratory phenotype, 
tracheal tissue was analyzed by Anna Ermund from the Mucin Biology Group at 
the University of Gothenburg, Sweden. For experiments on mucociliary transport, 
three airway-improved CF piglets, seven normal CF pigs and overall 14 WT 
animals have been analyzed. The studies revealed a mucus bundle velocity along 
the tracheal tissue of the improved animals which is at least as fast as in WT ones 
(see Figure 24 A). Typically, the examined normal CF piglets did not show any 
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movement of the mucus due to ciliary collapse. An additional scanning electron 
microscopic (SEM) analysis, visualized the more expanded mucus in the airways 
of an improved CF piglet, whereas in a normal CF pig, the mucus network seemed 
to be more compressed (see Figure 24 C). The appearance of the airway mucus 
network in an examined WT animal was comparable to the improved animal. 
Moreover, a measurement of the surface pH in tracheal tissue was performed in 
four modified piglets, 18 normal CFs and 20 WT piglets, resulting in a similar 
starting pH value of nearly 6.8 in the improved piglets and the WT controls (see 
Figure 24 B). Normal CF piglets exhibited a lower pH value of approximately 6.5. 
For a more detailed examination, the potential role of other modifier elements, in 
this case responsible for the variant respiratory phenotype, has to be investigated 
by future genome-wide mapping.   
 
Table 19: Final conditions for respiratory improved qPCRs. 
Gene Primer pair Concen. Annealing  
CFTR Lars2f/Lars2ra 0.5 µL 60 °C 
GAPDH GAPqf1/GAPqr1 0.5 µL 60 °C 
TBP tbpF/tbpR 0.7 µL 63 °C 
YWHAZ ywhazF/ywhazR 0.3 µL 63 °C 
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Figure 22: Relative quantification of CFTR expression in pulmonary tissue of 
respiratory improved CFTR-/- piglets (#5786, #6046) compared with normal 
CFTR-/- piglets (#5788, #6051) and a WT piglet (#6138). In contrast to the 
housekeeping genes GAPDH, TBP and YWHAZ that are generally expressed in all 
examined animals, a CFTR expression is only detectable in the WT control. Normal 
CF KO piglets as well as the airway-improved CF piglets typically lack an 
expression of CFTR. 
 
 
IV. Results    80 
 
Figure 23: Histopathological examination of bronchial tissue of a respiratory 
improved CFTR-/- piglet (#6046) compared with a normal CFTR-/- piglet 
(#6051). HE-staining of 4 % PFA-fixed tissue of the bronchus trachealis. In 
comparison to the normal CF piglet that exhibits a clearly reduced diameter, the 
diameter of the improved animal appears to be significantly enlarged. In both cases, 
the epithelium is lost due to tissue preparation (data kindly provided by Lars 
Mundhenk from the Institute of Animal Pathology at the Free University of Berlin, 
Germany). 
 
Figure 24: Further examination of tracheal tissue of respiratory improved 
CFTR-/- piglets compared with normal CFTR-/- piglets and WT piglets. (A) 
Analysis of the mucus bundle velocity. For visualizing, the mucus was stained with 
Alcian blue. The mean of five measurement points per time-lapse revealed that 
mucus transport in modified piglets is at least as fast as in WT ones, whereas 
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normal CFs did not show any mucus movement. (B) Surface pH measurement. 
Improved CF piglets and WT ones show a similar starting pH value of nearly 6.8, 
whereas normal CF animals exhibit a lower pH value of approximately 6.5. (C) 
Scanning electron microscopic (SEM) analysis. Red circles indicate the airway 
mucus network. Cilia are represented by yellow arrows. In the exemplary improved 
piglet, the mucus network seems to be more expanded than in the normal CF piglet 
that shows a more compressed network. The appearance of the airway mucus in the 
examined WT animal, is comparable to the modified pig (data kindly provided by 
Anna Ermund from the Mucin Biology Group at the University of Gothenburg, 
Sweden). 
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V. DISCUSSION 
Although Cystic Fibrosis remains incurable, the overall knowledge about this 
monogenic disease appearing with striking phenotypic diversity, increased 
tremendously (reviewed in WEILER & DRUMM, 2013; O'NEAL & KNOWLES, 
2018). Not only life expectancy, but also the quality of patients’ life has 
significantly been improved over the last decades. The development of first 
animal models for CF just shortly after the identification of the disease-causing 
CFTR gene in 1989 (RIORDAN et al., 1989; SNOUWAERT et al., 1992), 
significantly contributed to this successful progression. Animal models turned out 
to be essential tools for a better understanding of pathophysiological mechanisms 
in CF and for developing new therapeutic approaches (reviewed in 
SEMANIAKOU et al., 2018). From the CF animal models developed so far in six 
species, the porcine CF model proves to be the model showing the closest 
similarity to hallmark features of human CF disease (reviewed in CUTTING, 
2015) and it is therefore not surprising that CF pigs became an important model in 
CF research. However, a lethal neonatal intestinal obstruction by meconium 
represents a significant limitation in CF piglets. If MI is not corrected, CF piglets 
die within 48 hours after birth, considerably limiting the usage of pigs as animal 
models in CF research (KLYMIUK et al., 2012). While only 15-20 % of all CF 
infants (GUO et al., 2014) suffer from the intestinal obstruction, in CF piglets MI 
actually occurs with a penetrance of 100 % in both available CF pig models, in the 
United States as well as in Europe (ROGERS et al., 2008b; KLYMIUK et al., 
2012). Nonetheless, a previous thesis done at the Chair for Molecular Animal 
Breeding and Biotechnology, describes the occurrence of three CF piglets (#2850, 
#3137 and #4424) that showed a clear improved intestinal phenotype as 
meconium has passed autonomously; all other characteristic features of CF, such 
as mucus sticking in the airways, a triangular trachea, hypoplastic exocrine 
pancreas and a micro-gallbladder, were still present (DMOCHEWITZ, 2016). 
Genome-wide analysis suggested two independent modifying loci on chromosome 
10 (25.8–25.9 Mb) and on chromosome 16 (4.7–5.2 Mb) to rescue the severe 
intestinal phenotype. In my work, this hypothesis was tested. Therefore, the 
frequency of the promising genotype constellation on both candidate regions was 
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enriched in the CF breeding herd by selective breeding in order to increase the 
probability of the desired genotype constellation and the consequent expectation 
of additional CF piglets with an improved intestinal manifestation. 
 
The relevance of the genetic background for an improved intestinal phenotype 
was evaluated by a genome-wide survey of single nucleotide polymorphism 
(SNP) variations using the PorcineSNP60 DNA Analysis Kit v2 (Illumina, San 
Diego, USA). The PorcineSNP60 v2 BeadChip is the most comprehensive 
genome-wide genotyping array for the porcine genome (RAMOS et al., 2009; 
ILLUMINA, 2020). It has been validated in seven economically important pig 
breeds, including Duroc, Landrace, Pietrain, Large White as well as in wild boar 
as the ancestor of all modern pig breeds. The chip features more than 64,232 
SNPs that uniformly span the porcine genome with an average spacing of 43.4 kb, 
and thus enables a broad range of applications such as genome-wide selection, 
linkage disequilibrium studies, identification of quantitative trait loci, evaluation 
of genetic merit, cross-breed mapping, comparative genetic studies, and breed 
characterization for determining biodiversity. High call rates and accurate 
genotype calls ensuring the highest accuracy and reliability for successful whole-
genome association studies. Overall, validation of the PorcineSNP60 v2 
BeadChip proved it to be a valuable tool for most types of pig genetic studies 
(RAMOS et al., 2009). 
The AxiomTM Porcine Genotyping Array even includes 658,692 SNPs, validated 
in a diverse set of commercial and non-commercial pig breeds 
(THERMOFISHER). An accordance with 56,000 SNPs of the PorcineSNP60 v2 
BeadChip allows well compatibility with previous studies. A key benefit of this 
high-density array is the ability to genotype samples without experiencing marker 
dropout or missing data, which might occur with other porcine genotyping 
products. Compared with the PorcineSNP60 v2 BeadChip, the AxiomTM Porcine 
Genotyping Array offers the power for a more detailed fine mapping of the 
porcine genome. Nonetheless, considering the specification of the proposed 
haplotype constellation on chromosome 10 by six markers and on chromosome 16 
by ten markers, it is questionable whether a denser coverage of the proposed 
modifying loci would be favorable. These concerns appear even more true if the 
costs (approximately tenfold) are considered. The very same is true also for 
whole-genome surveys; although they would allow the most comprehensive 
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evaluation of a genome (in case of the nucleotide resolution). Further, analysis can 
only be performed in specialized laboratories and the evaluation requires specific 
bioinformatic equipment and expertise. Finally, at this point in time, whole-
genome approaches in the pig are limited by the low number of reference genome 
and would therefore require the sequencing of numerous control animals. For 
these reasons, we decided to do SNP typing with the PorcineSNP60 v2 BeadChip 
only. 
 
Although the marker-based haplotyping of animals is an effective and relatively 
cheap option for identifying candidate regions, its application in daily routine is 
difficult. This is not only due to the requirement of high-quality DNA, the scale of 
96 samples per run and the necessary access to specialized equipment, but also 
because genotyping of CF piglets needs to be carried out within the first hours 
after birth. To achieve this in a preferably simple, cheap and time-saving way, I 
established marker-specific genotyping PCRs. The discrimination PCRs 
distinguish the desired haplotypes at the modifier regions on chromosomes 10 and 
16 from unwanted ones. In total, every single piglet of a litter was characterized 
by performing seven PCRs. PCR for CFTR genotyping comprises two PCRs 
amplifying the WT and the mutated CFTR sequence. Five additional PCRs 
discriminate genetic constellations at the candidate regions on chromosomes 10 
and 16 (see chapter IV.1.1.2.). For marker 7 and marker 9 on chromosome 16, in 
each case, two individual PCRs were designed. One PCR determines the desired 
(“g”) haplotype, the second one detects the undesired (“b”) constellation. For 
marker 5 on chromosome 10 only one PCR was established that ruled out any 
unwanted haplotype. 
The marker-based genotyping was first used to enrich the desired haplotypes in 
the breeding herd. After screening all available pigs of the breeding herd for the 
potential modifier loci on chromosomes 10 and 16, the pigs have been mated 
selectively according to their haplotype constellations. By mating with unrelated 
WT animals, the frequency of the desired genotype constellation in the breeding 
animals has been increased. By selective breeding, I obtained the desired 
haplotypes on chromosome 10 and on chromosome 16 in 10 out of 55 CFTR-/- 
piglets (see chapter IV.1.1.3.). However, none of these animals showed the 
previously described autonomous release of meconium. Even a macroscopic and 
histological examination of the exemplary CF piglet #6491 with the desired 
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genetic constellation, did not reveal any indicative improvement of the intestinal 
phenotype compared to the CF piglet #6345 which lacked the wanted genotype. 
The initial hypothesis of two independent loci on chromosome 10 and on 
chromosome 16 to protect CFTR-/- piglets from MI was therefore clearly rejected. 
The influence of the genetic background on the intestinal phenotype in the CF pig, 
based on the report on three closely related CF piglets that had passed meconium 
autonomously, is still likely. However, the small number of affected CF piglets 
(three out of 23 CF piglets that showed the initial gut-improved phenotype) 
suggests a low frequency of a protective genetic constellation in the original 
breeding herd. Furthermore, I propose that by following a wrong initial 
hypothesis, the rare beneficial genotype constellation was finally sorted out. It is 
likely that both, the marker-based selection of breeding animals as well as the 
outbreeding with unrelated WT animals contributed to this elimination. 
 
Independently from the intestinal phenotype in CF pigs, a variant respiratory 
phenotype was observed in some CF piglets. During routine section it became 
obvious that three animals (#5703, #5704, #5786) differed from normal CF piglets 
by showing a WT-like round trachea with greater diameter, while their genotype 
and a significant MI clearly indicated common signs of CF (see chapter IV.2.2.). 
By systematically mating the parents of improved piglets (boar #5081, sow 
#5373), the randomly occurred improvement of the respiratory phenotype has 
been reproduced in two more CFTR-/- piglets (#6046, #6704). It is thus consequent 
to suppose that both, the intestinal as well as the respiratory phenotype in the CF 
pig are independently modified by variants of genetic background elements. A 
contribution of distinct genetic elements to the manifestation of the gut- and the 
lung-phenotype is very likely at the basis of the GWAS studies and reflects the 
situation in patients, where the phenotypical manifestation of CF in different 
organ systems uniquely responds to CFTR mutations and modifier effects 
(reviewed in WEILER & DRUMM, 2013; O'NEAL & KNOWLES, 2018). As 
early as 1990, the potential role of genetic modifiers in determining the 
complexity of CF, has been proposed (SANTIS et al., 1990). So far in human 
patients with CF, a variety of individual genetic modifiers for multiple CF 
phenotypes has been detected, though there is no single definitive contributor that 
universally predicts the disease severity or secondary complications (reviewed in 
DORFMAN, 2012). Rather combinations of several genetic variants seem to 
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contribute to overall disease manifestation.  
Regarding the intestinal phenotype, studies in CF twins and siblings undoubtedly 
indicate a predominant impact of additional non-CFTR genetic modifiers on both, 
the contribution to and the protection from MI (BLACKMAN et al., 2006). 
Subsequent genome-wide analyses on human CF patients revealed a few potential 
candidate loci, including polymorphisms in the genes coding for several members 
of the solute carrier family, either promoting (SLC6A14 on chromosome X, 
SLC9A3 on chromosome 13, SLC26A9 on chromosome 1) or preventing the 
development of MI (SLC4A4 on chromosome 4) (DORFMAN et al., 2009; SUN 
et al., 2012). Just recently, two new potential modifier genes of MI have been 
identified, namely ATPase H+/K+ transporting non-gastric alpha2 subunit 
(ATP12A) on chromosome 13, and a suggestive locus on chromosome 7 near 
serine protease 1 (PRSS1) (GONG et al., 2019). 
In CF patients carrying an identical CFTR genotype it was determined that genetic 
modifiers could account for 50-80 % of lung disease variability (VANSCOY et 
al., 2007). For the divergent pulmonary phenotype in humans, numerous modifier 
genes have been described, with transforming growth factor beta 1 (TGFB1) and 
mannose-binding lectin (MBL) being the first ones that have been identified 
(reviewed in SHANTHIKUMAR et al., 2019). Apart from TGFB1 and MBL, 
there are other genes that have been suggested as potential modifiers, such as 
homeostatic iron regulator (HFE) (REID et al., 2004; PRATAP et al., 2010; 
SMITH et al., 2019), endothelin receptor type A (EDNRA) (DARRAH et al., 
2010) and carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 
(STANKE et al., 2010). 
In contrast to the significant evidence of modifier genes for human CF disease, 
none such elements have been described in the pig so far. The most striking 
explanation for this finding is the limited number of CF piglets that have been 
produced. Even if the number of such animals in the US and European breeding 
herds reaches a several hundreds, the obviously limited genetic diversity in the 
breeding herds descending from a handful of individuals and their systematic 
breeding for less than ten generations, would prevent a constellation similar to 
humans where founder individuals have distributed their mutations among huge 
populations for centuries. Therefore, the appearance of unusual phenotypes in 
closely related CFTR-/- piglets showing either autonomous remove of meconium 
or a WT-like anatomy of the trachea, must be seen as strong evidences that also in 
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CF pigs modifier genes might play a crucial role in altering disease severity. 
 
In parallel to testing the hypothesis of modifier loci on chromosome 10 and on 
chromosome 16 by marker-assisted breeding, a detailed analysis of the candidate 
region on chromosome 10 has been conducted. Based on the assumption that a 
potential causative mutation would preferentially be located in a region with a 
specific function and that such functional region would often be conserved 
between species, we performed a multi-species alignment of the candidate region 
on chromosome 10 and identified genetic elements proposed by different 
prediction tools. This procedure suggested three regions of several kb size which 
were therefore examined by Sanger sequencing in animals of the different marker-
defined haplotypes “g/g”, “g/b” and “b/b”. The identified SNPs in locus 1 and 
locus 2 did not reveal a pattern according to the marker-based analysis, and locus 
3 did not reveal any polymorphisms between the different c105 haplotypes. As 
this finding correlated to the results from the selected breeding procedure, the 
initial hypothesis of modifier regions on chromosome 10 and on chromosome 16 
was finally rejected. For reasons of completeness, however, one could question, if 
not a region outside the three examined loci contained a genetic variant 
responsible for the differences in the intestinal phenotype. Although this cannot be 
excluded, I think the assumption of functional properties in conserved and/or 
annotated genetic elements is a valuable and efficient strategy. Notably, not only 
the GeneScan tool predicted locus 1 and locus 2 as significant genetic elements, 
but both loci are also characterized by high homology among different species. 
Assuming the maintenance of genetic elements during the evolution only in the 
case of a beneficial function, this finding implies a potential regulatory function of 
locus 1 and locus 2. The finding of a potential regulatory capacity of two loci by 
the PreMod database, supports this consideration. No other region within the 
candidate region on chromosome 10, except the terminal exon of NEK7 (locus 3) 
showed similar evidence for a potential regulatory function. On the other hand, 
there is also evidence that such biased assumptions do not always correctly 
identify all regulatory elements. This is particularly true if such elements are 
species-specific. Two such examples have previously been published in the cattle: 
The first one was the responsibility of genetic duplications, located in a large 
intergenic region, for genetically induced lack of horn (MEDUGORAC et al., 
2012). Although the mechanism of how these mutations prevent the growing of 
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horn is not completely understood (reviewed in ALDERSEY et al., 2020), the 
introgression of such a modification by gene editing proved transformation of a 
horned cattle genome into a polled version (TAN et al., 2013). The second one 
was the identification of a common, dominant genetic variant that causes a white 
belt around the body of otherwise colored cattle (AWASTHI MISHRA et al., 
2017; ROTHAMMER et al., 2018). Again, the causative mutation is fairly distant 
to its closest annotated genetic element, TWIST2. Importantly, however, both 
phenotypic characteristics, the formation of horned appendices at the skull bones 
and the coloring of fur are definitely species-specific artifacts which is in strong 
contrast to the functional conservation of the CFTR-encoded anion channel. 
Since the examination of chromosome 10 did not provide a possible explanation 
for a diverse manifestation of the CF gut-phenotype, and although I succeeded in 
enriching the desired genotype constellation on chromosome 10 and on 
chromosome 16 in almost 10 CFTR-/- piglets, but none of them showed an obvious 
improvement regarding the intestinal obstruction by meconium, the second 
postulated candidate region on chromosome 16 was not taken in further 
consideration. 
 
Although the initial hypothesis of two independent loci on chromosomes 10 and 
16 to protect CF piglets from MI has clearly been rejected by different methods, 
the assumption of a genetic background influencing the severity of the CF gut-
phenotype appeared still convincing. Therefore, we conducted a second genome-
wide survey (see also chapter IV.1.2.). For SNP-typing we employed the same 
genotyping array as used for the first analysis, namely the PorcineSNP60 v2 
BeadChip (Illumina, San Diego, USA), but this time mapping was performed 
under more favorable conditions. Not only the amount of examined CF piglets 
showing the typical MI was extended to overall 198 animals, including 143 
animals that have been investigated in the first GWAS and 55 additional piglets, 
but also 14 new heterozygous breeding animals have been incorporated into the 
pedigree. By integrating an extended population of control animals in the 
genotyping, the probability to figure out appropriate candidate regions along the 
porcine genome allowing for a proper distinction between the modified and the 
normal gut-phenotype in CF pigs, is increasing respectively. To analyze the 
obtained data, an alternative method based on a combined linkage disequilibrium 
and linkage analysis (cLDLA) has been applied corresponding to the method 
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proposed by MEUWISSEN et al. (2002). The cLDLA approach, based on 
reconstructed haplotypes, facilitate a more precise mapping and proved to be less 
sensitive to the absence of error-free marker maps and perfectly associated SNP 
than the SNP-GWAS approach (MEDUGORAC et al., 2017; MÜLLER et al., 
2017). In view of promising results that have been realized in former studies, the 
alternative cLDLA method was considered as a useful complementary approach 
to the standard GWAS (ROTHAMMER et al., 2014; KUNZ et al., 2016). In this 
way, the analysis of our extended data set revealed two alternative candidate 
regions on chromosome 5 and on chromosome 13 potentially modifying the 
severity of the CF intestinal phenotype in pigs. A further examination of the two 
loci resulted in interesting features: 
The first candidate region on chromosome 5 is packed by almost 12 genes. 
Because it is difficult to predict a causative variation among this high density of 
genes, the expression rate of every gene or genetic element in a broad spectrum of 
different organs as well as their described function according to the current 
literature has been checked in order to estimate a possible impact on modifying 
the CF gut-phenotype. In doing so, ATP6V1E1, located within the center of the 
candidate region, turned out to be a very promising one as its encoded protein is a 
component of the multi-unit vacuolar ATPase, a proton pump acting on the 
acidification of intracellular organelles and extracellular compartments 
(MCGUIRE et al., 2017). In view of an impaired regulation of the pH in the case 
of lacking CFTR, the involvement of ATP6V1E1 in compensating this deficit, 
constitutes a logical approach. The consequences of lacking CFTR on lysosomal 
acidification are discussed contradictory (TEICHGRABER et al., 2008; HAGGIE 
& VERKMAN, 2009), however, there is no doubt about a co-localization of the 
vacuolar ATPase with CFTR on the apical side of respiratory epithelial cells 
(JAKAB et al., 2013; PLASSCHAERT et al., 2018). It is interesting to note that 
in human and other mammalian species, another anion channel, SLC25A18, is 
included in this region, but in sheep, cattle and pig it is lacking due to a large 
genomic deletion. Therefore, it has not been considered as a possible modifier of 
the intestinal phenotype in the CF pig model.  
The second candidate region on chromosome 13 comprises only four genes and an 
implemented haplotype analysis restricted the region to a size of 180 kb. This 
segment resembles the upstream region of TGFBR2, including some of its well-
characterized enhancer elements. While this region is apparently lost in pair-toed 
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species, it is partially highly conserved in the other investigated animals. TGFB is 
well known to modify pulmonary disease in CF (DRUMM et al., 2005; BREMER 
et al., 2008) and also its function as a promoter of growth in the intestinal 
epithelium is considered as secure (BARNARD et al., 1989). TGFBR2 itself plays 
an important role in cell proliferation, including the continuous turnover of 
epithelial cells in the gut (FLENTJAR et al., 2007; ZHANG et al., 2016). A loss 
of function causes structural and functional damage of intestinal organoids 
(IHARA et al., 2018). Interestingly, a recent study of KLUGE et al. (2019) 
demonstrated a direct interaction between the TGFB-signaling axis and 
ATP6V1E1 in regulating the extracellular bicarbonate concentration by epithelial 
cells. This finding supports the assumption of an independent or synergistic 
involvement of both proposed genes in controlling the extracellular pH and 
bicarbonate concentration of the intestine. 
Taken together, an involvement of genetic variants of ATP6V1E1 on chromosome 
5 as well as TGFBR2 on chromosome 13 in modifying the severity of the gut-
phenotype in CF pigs deserves further attention. However, the new hypothesis has 
to be verified in future studies, whereby a more detailed characterization of the 
two submitted modifier genes is necessary. A first attempt would be the detailed 
sequencing of the candidate region, which has become a valuable approach due to 
the dramatically decreasing costs of whole-genome sequencing approaches. On 
the other hand, the limited availability of reference genomes as well requires the 
examination of numerous control animals, which makes this approach a 
demanding exploration. Second, the reproduction of suitable parental animals 
might produce new CF piglets with an improved phenotype and facilitates a more 
profound analysis of the genetic background. However, both strategies are time-
consuming and therefore could not be conducted during my thesis. So far, there is 
good evidence for an influence of the genetic background on the gut-phenotype in 
our CF pig herd, but the exact molecular constellation still has to be identified. 
Pursuing the idea of a marker-assisted breeding will help to shape the genetic 
constellation of the breeding animals towards a regular production of CF piglets 
with an improved intestinal phenotype. Surviving the first critical days of life, will 
make the CF pig an ideal animal model for CF. It paves the way for a better long-
term evaluation of the disease and allows for systematic preclinical testing of 
potential new forms of Cystic Fibrosis therapy. 
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As the new respiratory phenotype constitutes an interesting new modification of 
the CF pig model, it is crucial to analyze it in more detail. For a more precise 
description, it will be essential to increase the number of experimental animals. 
Since we did not obtain further animals with a similar modification of the 
respiratory CF phenotype after retiring the parental animals of the improved 
piglets from our breeding herd, new CF piglets must be generated in another way. 
One possible option is the re-cloning of one of the modified CF piglets via SCNT 
and ET. The production of airway-improved CF pigs by re-cloning is a fast and 
efficient method to generate a small number of animals with the desired genotype. 
However, it has to be considered that the re-cloned piglets might not exhibit the 
same level of improvement as the donor animals or even do not show any 
modification compared with normal CF piglets. In addition, this method is not 
suitable to produce a large number of viable animals due to a usually low cloning 
efficiency and a high rate of phenotypical abnormalities, so-called cloning 
artefacts, that might be explained with epigenetic reprogramming or genomic 
damage of the donor cells (CHO et al., 2007; HÖRMANSEDER et al., 2017). 
Alternatively, the parental animals of the airway-improved CF piglets themselves 
could be re-cloned and selectively mated at sexual maturity enabling a 
conventional breeding of a larger number of piglets.  Nevertheless, this approach 
is very time-consuming and again, it is not certain if the resulting CF piglets will 
exhibit the desired phenotypical modification of the airways.  
The new improved respiratory phenotype in the CF pig opens new prospects for 
the Cystic Fibrosis research and can thereby lead to a better understanding of 
pathophysiological mechanism of the disease.  
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VI. SUMMARY 
Modifier genes of the intestinal and respiratory phenotype in Cystic Fibrosis 
pigs 
Cystic Fibrosis (CF) is the most common lethal, autosomal recessive hereditary 
disease among Caucasians and affects more than 100,000 people worldwide. It is 
caused by mutations in the gene coding for the anion channel Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR), leading to a defective 
transepithelial electrolyte transport. While CF constitutes a multisystemic disease 
mainly affecting the airways, the gastrointestinal tract and the pancreas, the major 
cause for the decreased survival rate of CF patients is traced to pulmonary 
insufficiency. The overall knowledge about the disease increased tremendously, 
so that not only life expectancy of up to 40 years, but also the quality of patients’ 
life has significantly been improved over the last decades. 
From the CF animal models developed so far in six species, the porcine CF model 
proves to be the model showing the closest similarity to human CF disease. 
However, since a lethal neonatal meconium ileus (MI) occurs in 100 % of all CF 
piglets, the use of the pig as an animal model for CF is strongly limited. 
Nonetheless, a previous thesis done at the Chair for Molecular Animal Breeding 
and Biotechnology, describes the occurrence of three CF piglets that showed an 
improved intestinal phenotype as meconium has passed autonomously. An 
implemented genome-wide association study resulted in the hypothesis of two 
potential modifier loci on chromosome 10 (25.8–25.9 Mb) and on chromosome 16 
(4.7–5.2 Mb) to rescue the severe gut-phenotype, whereby the three rectified 
piglets were homozygous for a specific haplotype at both loci.  
As the aim of my thesis was to test this hypothesis, it was necessary to enrich the 
desired genetic constellation on both candidate regions in the CF breeding herd in 
order to increase the probability of generating CF piglets with the specific 
haplotypes. For this purpose, the CF breeding herd was screened for the proposed 
modifier loci by detecting informative markers. In addition, marker-specific PCRs 
have been established that discriminate the desired haplotype from any of the non-
desired constellations. By selected mating, I succeeded in enriching the wanted 
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genotype in 10 CF piglets, but none of these animals showed the previously 
described improvement of the gut-phenotype. This finding was confirmed by a 
macroscopic and histological examination and correlated to the detailed SNP-
based examination of the candidate region on chromosome 10 as the identified 
SNP patterns were not consistent with the marker-defined haplotypes. The initial 
hypothesis of a beneficial influence of the postulated regions on chromosomes 10 
and 16 was therefore fully rejected. Instead, an alternative investigation of a more 
extended population of CF animals, based on a combined linkage disequilibrium 
and linkage analysis (cLDLA), revealed two new candidate regions on 
chromosome 5 and on chromosome 13 and suggested the potential involvement of 
genetic variants of ATP6V1E1 (chromosome 5) and TGFBR2 (chromosome 13). 
Independently from the CF gut-phenotype, a variant respiratory phenotype was 
observed in some CF piglets during my thesis. These animals differed from 
normal CF piglets by showing a WT-like round trachea with greater diameter, 
while their genotype and a significant MI clearly indicated common signs of CF. 
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VII. ZUSAMMENFASSUNG 
Modifier-Gene des intestinalen und respiratorischen Phänotyps in Schweinen 
mit Mukoviszidose 
Die Mukoviszidose, auch zystische Fibrose (ZF) genannt, stellt die häufigste 
tödliche, autosomal rezessive Erbkrankheit unter Kaukasiern dar und betrifft 
weltweit mehr als 100.000 Menschen. Sie wird verursacht durch Mutationen im 
Gen, das für den Anionenkanal Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR) codiert, welche zu einem fehlerhaften transepithelialen 
Elektrolyttransport führen. Obwohl ZF eine multisystemische Erkrankung 
darstellt, welche hauptsächlich die Atemwege, den Verdauungstrakt sowie das 
Pankreas betrifft, ist die Hauptursache für die eingeschränkte Lebenserwartung 
der ZF-Patienten auf eine Lungeninsuffizienz zurückzuführen. Das allgemeine 
Wissen um die Krankheit hat sich enorm erweitert, sodass sich in den 
vergangenen Jahrzehnten nicht nur die Lebenserwartung der Patienten auf bis zu 
40 Jahren erhöhte, sondern sich auch deren Lebensqualität signifikant verbesserte.  
Von den bislang entwickelten sechs ZF-Tiermodellen, erweist sich das porcine 
Modell als dasjenige, welches die größte Ähnlichkeit mit der menschlichen ZF-
Erkrankung aufweist. Dennoch ist der Nutzen des Schweins als Tiermodell für die 
Mukoviszidose stark begrenzt, da in 100 % aller ZF-Ferkel ein tödlicher 
neonataler Mekoniumileus (MI) auftritt. Nichtsdestotrotz beschreibt eine 
vorhergehende Doktorarbeit, erarbeitet am Lehrstuhl für Molekulare Tierzucht 
und Biotechnologie, das Vorkommen von drei ZF-Ferkeln, welche durch das 
selbstständige Absetzen von Mekonium einen verbesserten intestinalen Phänotyp 
aufzeigten. Eine durchgeführte genomweite Assoziationsstudie resultierte in der 
Hypothese zweier möglicher Modifier-Regionen auf Chromosom 10 (25,8-25,9 
Mb) und auf Chromosom 16 (4,7-5,2 Mb), die vor einer schwerwiegenden 
Ausprägung des Darmphänotyps bewahren sollen, wobei die drei verbesserten 
Ferkel homozygot für einen bestimmten Haplotyp auf beiden Regionen waren. Da 
es das Ziel meiner Doktorarbeit war, diese Hypothese zu testen, war es 
notwendig, die gewünschte genetische Konstellation auf beiden 
Kandidatenregionen in der ZF-Zuchtherde anzureichern, um die 
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Wahrscheinlichkeit zu erhöhen, ZF-Ferkel mit den spezifischen Haplotypen zu 
produzieren. Aus diesem Grund wurde die ZF-Zuchtherde auf die 
vorgeschlagenen Modifier-Regionen überprüft, indem aussagekräftige Marker 
festgestellt wurden. Darüber hinaus wurden markerspezifische PCRs etabliert, 
welche den gewünschten Haplotyp von allen unerwünschten Konstellationen 
unterscheiden. Durch gezielte Verpaarung gelang es mir, den gesuchten Genotyp 
in 10 ZF-Ferkeln anzureichern, aber keines dieser Tiere zeigte die zuvor 
beschriebene Verbesserung des Darmphänotyps. Dieses Ergebnis wurde mit Hilfe 
makroskopischer und histologischer Untersuchung überprüft und korrelierte mit 
der ausführlichen, auf SNPs basierenden Untersuchung der Kandidatenregion auf 
Chromosom 10, da die Muster der identifizierten SNPs nicht mit den marker-
definierten Haplotypen übereinstimmten. Die ursprüngliche Hypothese eines 
günstigen Einflusses der vorgeschlagenen Regionen auf den Chromosomen 10 
und 16 wurde deshalb vollständig widerlegt. Stattdessen brachte die alternative 
Untersuchung eines erweiterten ZF-Tierbestandes, beruhend auf der cLDLA-
Methode, zwei neue Kandidatenregionen auf Chromosom 5 und auf Chromosom 
13 zum Vorschein und unterstellte eine mögliche Beteiligung genetischer 
Varianten von ATP6V1E1 (Chromosom 5) und TGFBR2 (Chromosom 13). 
Unabhängig vom ZF-Darmphänotyp konnte während meiner Doktorarbeit in 
einigen ZF-Ferkeln ein abweichender respiratorischer Phänotyp festgestellt 
werden. Diese Tiere unterschieden sich von normalen ZF-Ferkeln, indem sie eine 
WT-ähnliche runde Trachea mit größerem Durchmesser aufwiesen, wohingegen 
ihr Genotyp sowie ein signifikanter MI eindeutig auf übliche Anzeichen von 
Mukoviszidose hinwiesen. 
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